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Maternal nutrient restriction (NR) causes small for gestational age offspring 
(SGA), which exhibit a higher risk for metabolic syndrome. Skeletal muscle is among 
the most susceptible organs to maternal NR. Previous studies have typically considered 
NR fetuses as a single experimental group. However, using a sheep NR model, we 
routinely observe a spectral phenotype of fetal weights within the NR group, suggesting 
unique maternal-placental adaptations and fetal responses. Hence, studies were 
conducted to characterize particular aspects of fetal skeletal muscle growth and 
pathways for glucose uptake, while considering fetal weight variations within the NR 
group.  
Singleton pregnancies (n=56) were generated by embryo transfer. Ewes received 
100% (Control, n=12) or 50% (NR, n=44) of NRC nutrient requirements from 
gestational day (GD) 35 until necropsy at GD 135, when gastrocnemius and soleus 
muscles were collected. NR fetuses were separated into quartiles based on fetal weight, 
the highest (Non-SGA, n=11) and lowest (SGA, n=11) quartiles were selected for 
investigation. Results for muscle growth showed decreased cross-sectional area in both 
muscles within NR(SGA) group compared to controls, without alterations in pathways 
for protein synthesis (MTOR) or degradation (Glucocorticoid-KLF15-ubiquitin ligases) 
regardless of upregulation in KLF15 (in gastrocnemius) and BCAT2 (in soleus) in  




amino acids, which suggests that lower availability of building blocks is a limiting factor 
for protein synthesis rate, without downregulating pathways involved in this process.  
Results for glucose uptake pathways showed an increase of insulin and IGF1 
receptors in response to a decrease of those hormones, and higher content of the glucose 
transporters SLC2A4 and SLC2A1 in NR(SGA) fetuses within gastrocnemius. These 
metabolic adaptations would support fetal survival while predisposing for metabolic 
dysregulations in adulthood. In both muscles, NR(SGA) group had lower type I 
myofiber proportion which if maintained postnatally would further affect metabolism. 
 Collectively, these results highlight that while most responses within NR(SGA) 
group are concordant with previous observations for SGA offspring, our NR(Non-SGA) 
group represents a different phenotype that is not entirely protected from NR 
programming, despite being of normal fetal weight. Results also identify muscle-specific 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
 Long-term maternal nutrient restriction (NR) during pregnancy impairs fetal 
growth, which leads to small for gestational age (SGA) offspring. This condition is 
associated with higher perinatal mortality and increased risk of metabolic syndrome 
during postnatal life (Barker et al., 1989). Skeletal muscle is among the most sensitive 
tissues to maternal NR, and it plays an essential role in metabolic dysregulation due to its 
prominence in glucose and oxidative metabolism (Brown, 2014). Additionally, the 
occurrence of SGA offspring in livestock species is associated with a decrease in 
productive performance, mostly in meat production, which depends on efficient skeletal 
muscle growth and metabolism. This becomes particularly relevant as current estimations 
suggest that worldwide protein production should be doubled by 2050 to meet the 
requirements of an increasing human population (Alexandriatos and Bruinsma, 2012). 
The situation becomes even more concerning when considering that hunger remains a 
severe problem in developing countries, in areas such as Africa and Asia (FAO, 2017). 
 The use of a livestock animal research model, such as the sheep, to understand 
the effect of maternal undernutrition in skeletal muscle growth and metabolism 
provides valuable information for translational research as well as insights to prevent 






1. Undernutrition and Low Birth Weight Prevalence in the World 
 Malnutrition has been defined by the World Health Organization (WHO) as any 
condition leading to overnutrition and obesity, famine and underweight, or dysregulation 
in intake of specific minerals and micronutrients (FAO, 2017). By 2017, more than one in 
every eight adults in the world were obese, and around one in nine were undernourished, 
which was estimated to represent a total of 821 million of undernourished people around 
the world. Famine and undernutrition cases have been continuously increasing since 2014 
and are a public health concern primarily in developing and low-income countries (FAO, 
2017). This is represented by the distribution of undernutrition in the world, where Africa 
represents 20.4%, Asia represents 11.4%, and Latin America and The Caribbean 
represent 6.1%, while less than 2.5% is represented by North American and Europe 
together (FAO, 2017). 
 The consequences of undernutrition are ample and include a higher predisposition 
for disease, and in extreme situations, death. This scenario becomes particularly 
challenging during periods of physiological increase of nutrient requirements; such as 
pregnancy since the female organism must support itself as well as placental and fetal 
growth. Maternal undernutrition during pregnancy results in SGA offspring, with more 
than 20 million cases reported annually (UNICEF, 2004). As expected, the distribution of 
low birth weight cases matches the geographical areas of adult undernutrition as 95.4% of 
the cases appear in developing countries, with most of them occurring in Asia and Africa, 





2. Maternal Nutrient Restriction and SGA Offspring 
 Low birthweight neonates include both, preterm births and infants born to term 
after experiencing intrauterine growth restriction. For humans, the concept of intrauterine 
growth restriction (IUGR) has been defined as the offspring placed below the 10th  
percentile of fetal weight distribution at birth, and it is typically associated to asymmetric 
growth (Goldenberg and Cliver, 1997). In livestock species, maternal nutrient restriction 
is also a prevalent cause for IUGR, which have been defined as an impairment in 
gestational development of a fetus or its parts (Wu et al., 2006). A similar concept is 
small for gestational age (SGA) offspring, which is a broader classification and refers to 
fetuses that are smaller than expected for the species at a given gestational age 
(Goldenberg and Cliver, 1997). Individuals born as IUGR or SGA are more prone to 
suffer perinatal mortality and experience an increased risk for hypertension (Gennser et 
al., 1988), obesity (Fernandez-Twinn and Ozanne, 2006), type 2 diabetes (Rich-Edwards 
et al., 1999), heart disease (Barker et al., 1989) and metabolic syndrome (McMillen and 
Robinson, 2005). 
 Dr. David Barker was the first scientist to describe this correlation between 
maternal nutrient restriction, birth weight, and postnatal metabolic dysregulations. Based 
on studies conducted on adult offspring born to undernourished females during the Dutch 
famine, Hales and Barker (1992) stated the thrifty phenotype hypothesis. This hypothesis 
states that early life nutrient deficiency leads to a fetal programming effect that would 
support immediate survival and promote storage of nutrients, predominantly in the form 




postnatal life, these adaptations would lead to type 2 diabetes, obesity, and other 
dysregulations associated with metabolic syndrome (Symonds et al., 2009). The 
appearance of these conditions would be exacerbated by a postnatal scenario of normal, 
or excessive, nutrient availability. In this case there will be a mismatch between the 
prenatally anticipated environment and the actual postnatal conditions; consequently, the 
fetal adaptations to survive under prenatal nutrient scarcity will turn into negative health 
outcomes later in postnatal life (Gluckman et al., 2005; Hyatt et al., 2011). 
3. Maternal Nutrient Restriction and Livestock Production 
 In addition to its effects on human health, maternal undernutrition also affects the 
production potential of livestock species (Wu et al., 2006). Animals that are usually 
raised based on grazing systems, such as sheep and cattle, are among the most susceptible 
to be affected due to low forage quantity and quality. Nowadays, climate change is a 
global factor that negatively impacts the natural environment (Walther et al., 2002) and 
has a direct detrimental effect on forage availability for livestock species. Alterations in 
rainy and drought periods, increase in desertification, and changes in temperature are 
likely to produce forage scarcity, and projections indicate that this situation will become 
even more severe in the future (Howden et al., 2008; Nardone et al., 2010). 
 This scenario of nutrient scarcity becomes even more critical under physiological 
conditions such as pregnancy, when the dam has to support its requirements, in addition 
to placental and fetal growth (Bauman and Currie, 1980). As a consequence, fetal growth 
is reduced in response to nutritional hardship, which in the context of livestock species 




SGA offspring is under a higher risk of neonatal death, which leads to economic losses 
for the industry. Impaired thermogenesis capacity is one of the causes of increased 
neonatal death in SGA neonates. Brown adipose tissue (BAT) plays an essential role in 
non-shivering thermogenesis, a primary mechanism for thermoregulation in the neonate 
(Satterfield and Wu, 2011). BAT development is impaired by maternal NR as 
demonstrated by a model of 50% NR in the sheep, which led to a decrease in fetal brown 
adipose tissue (BAT) weight (Satterfield et al., 2013). Interestingly, the study of 
Satterfield et al. (2013) found that arginine administration to 50% NR ewes was sufficient 
to rescue BAT growth to control levels, which would have a positive effect on neonate 
survival in fetuses from NR dams.  
 Additionally, animals born as SGA after prenatal nutrient restriction present a 
reduced efficiency in nutrient utilization (Wu et al., 2006) and experience an accelerated 
compensatory growth that favors adipose tissue deposition instead of skeletal muscle (De 
Blasio et al., 2007). This raises production costs and alters carcass composition towards 
increased fat and decreased lean mass (Ford et al., 2007), which reduces carcass value. 
Moreover, skeletal muscle development and growth are impaired by maternal nutrient 
restriction (Fahey et al., 2005; Quigley et al., 2005; Zhu et al., 2006; Costello et al., 2008; 
Brown, 2014)  and this effect cannot be fully compensated during postnatal life because 
the number of muscle fibers is fixed before birth in livestock species (Picard et al., 2002). 
Hence, the capacity for lean mass deposition would be permanently diminished as a result 




 A decrease in animal protein production as a result of maternal NR will have an 
impact on human nutrition and health because animal protein is an essential source of 
nutrients for the human population (Wu, 2016). Beyond its relevance in animal 
production, nutritional hardship in livestock species such as the sheep has also been 
recognized as a suitable model for translational research in fetal development (Barry and 
Anthony, 2008; Morrison, 2008). This allows for dual-purpose research with the potential 
to provide valuable knowledge for both fields, animal production, and human health and 
physiology.  
4. Maternal Nutrient Restriction Effect on Fetal Organ Growth and 
Function – Sheep Model  
The use of animal models for the study of fetal programming has provided 
supporting evidence for the initial epidemiological associations between maternal 
nutrient deprivation, SGA offspring, and metabolic alterations in postnatal life. 
Among different animal models, the sheep is a valuable alternative in an agricultural 
context, and for application into translational research, because it represents a close 
approximation to the level of maturity and organ development of a human fetus 
(Figure 1.1), it is a non-litter bearing species, and ovine fetuses are similar in size to 





Figure 1.1 Comparative Organogenesis Timeline throughout Human, Sheep, and 
Mouse Gestation.  Mouse offspring are born precocial and development of organs such 
as muscle and kidney is completed postnatally. When compared to the human timeline 
for development, the sheep represents a closer approximation than mouse. Both kidney 
and muscle development are completed prenatally in the sheep and human. Prenatal 
alterations in either kidney or muscle development would have the potential to be 
corrected postnatally in the mouse, while this potential will be low in sheep and human. 
A similar developmental timing is beneficial when translational research is the goal of 
fetal programming studies. NT (neural tube), 1° Myo (primary myogenesis of skeletal 
muscle), Emb (embryonic lung development), Pseudo (pseudoglandular lung), Canal 






 Several studies have been conducted in the sheep to evaluate the effect of 
maternal NR in fetal organ growth and metabolism. A decrease in fetal weight has been 
a seminal finding of these studies (Osgerby et al., 2002; Kwon et al., 2004; Gao et al., 
2008; Lassala et al., 2010; Satterfield et al., 2009; Satterfield et al., 2013).  The study of 
Kwon et al. (2004) showed that decreased fetal growth in response to maternal NR was 
associated to a reduced concentration of polyamines and amino acids (branched-chain 
amino acids, serine, and arginine) in maternal and fetal plasma, as well as fetal allantoic 
and amniotic fluid. Realimentation of NR females from gestational day (GD) 78 to term 
was shown to prevent impaired fetal growth in this study (Kwon et al., 2004). 
Interestingly, the study of  Lassala et al. (2010)  found that decreased fetal weight in 
response to maternal NR could be prevented by administration of arginine from GD 60 
to term, which further reinforces the relevance of amino acid availability for normal fetal 
growth.  
 Also, lower circulating levels of insulin like growth factor 1 (IGF1) and insulin 
have been reported in fetal plasma as a consequence of maternal NR (Osgerby et al., 
2002). Both IGF1 (Baker et al., 1993)  and insulin (Fowden et al., 1989) play an 
essential role in the stimulation of fetal growth. 
 Growth and metabolism in several fetal organs are affected by maternal NR in 
the sheep. Examples of these findings are ventricular hypertrophy in fetal heart 
(Vonnahme et al., 2003), impaired vasodilation capacity in coronary arteries (Shukla et 
al., 2014); and decreased glomeruli dotation (Brenner et al., 1988) and upregulated 




(Osgerby et al., 2002) and brown adipose tissue (Satterfield et al., 2013) have been 
described. Interestingly, pancreatic and brown adipose tissue growth was increased after 
maternal arginine administration (Satterfield et al., 2013). For liver, increased relative 
weight has been found at the fetal stage by GD 78 (Vonhamme et al., 2003), while 
decreased liver weight accompanied by increased expression in apoptotic factors was 
found in aged offspring after prenatal NR (Hyatt et al., 2007). Increased expression of 
PEPCK, a rate-limiting enzyme for gluconeogenesis, has also been found in the liver of 
aged offspring born to NR ewes (George et al., 2012).  
 For skeletal muscle, a reduction of myofiber number (Quigley et al., 2005) , 
hypertrophy (Zhu et al., 2004) and muscle mass (Fahey et al., 2005) in addition to 
metabolic alterations regarding oxidative capacity (Zhu et al., 2006), and glucose 
metabolism (Costello et al., 2008) have been observed in response to maternal NR. 
Skeletal muscle represents around 40% of total body mass in an adult organism (Janssen 
et al., 2000), and around 80% of insulin-mediated glucose uptake occurs in this tissue 
(Ferrannini et al., 1985; DeFronzo and Tripathy, 2009). Thus, alterations in muscle 
development or metabolism can have profound impacts in the metabolic dysregulation 
typically seen in SGA offspring. Therefore, studying the effect of prenatal nutrient 
scarcity on skeletal muscle development, growth, and metabolism is essential to 






5. Overview of Skeletal Muscle Development and Growth 
5.1 Myogenesis 
 Skeletal muscle development and growth during the fetal stage are accomplished 
by both, cellular hyperplasia and fusion to originate myofibers (myogenesis), and 
hypertrophy, which continues postnatally. Myogenesis can be divided into primary and 
secondary myogenesis.  
 Primary myogenesis represents the first wave of myofiber formation, accounts 
for a small percentage of myofibers in the adult and occurs in early pregnancy during the 
embryonic stage. Specifically, in the sheep, it starts around GD 35 (Maltin, 2008). 
During primary myogenesis, skeletal muscle precursors called myoblasts fuse to form a 
primary myotube which will then become a primary myofiber.  
 Secondary myogenesis starts around GD 62 and accounts for the majority of 
myofiber formation (Maltin, 2008). During this process, myoblasts fuse to form 
secondary myotubes around the primary myotubes, which serve as a template, then 
secondary myotubes become myofibers. Before their fusion to form myotubes, 
myoblasts can proliferate. Myoblast hyperplasia is essential to provide myogenic 
precursors, and this process is stimulated by the activation of pathways that typically 
induce cell proliferation, such as mitogen-activated protein kinase 1 (MAPK1) (aka 
ERK) (Jones et al., 2001). 
 During embryonic and fetal development, there are common mesenchymal stem 
cell precursors from which skeletal muscle develops. Commitment to the myogenic 




mesenchymal stem cells precursors, which is in part controlled by the Wingless-type 
MMTV integration site family (WNT) pathway. An increase in WNT signaling will 
activate catenin beta 1 (CTNNB1) (aka beta-catenin) to induce expression of paired box 
3 (Pax3) and paired box 7 (Pax7), which are markers of differentiation towards a 
myogenic cell lineage. As a result, there will be an upregulation of myogenic regulatory 
factors (MRFs) (Cossu and Borello, 1999). MRFs include myogenic differentiation 1 
(MYOD1) and myogenic factor 5 (MYF5), which promote the conversion of precursor 
cells into myoblasts; myogenin, which is involved in the fusion of myoblasts to form 
myotubes; and myogenic factor 6 (MYF6) (aka MRF4), which is involved in the 
maturation of myotubes to form myofibers (Figure 1.2) (Stewart and Rittweger, 2006).  
 Developmental timing is essential in the context of organ susceptibility for 
programming. In the case of skeletal muscle, because the active formation of new 
myofibers occurs during early to mid-gestation, it is expected that environmental insults 
applied during this stage would primarily impair the number of formed myofibers. This 
effect cannot be reversed postnatally because myofiber formation is not an active 



















Figure 1.2 Schematic Representation of Skeletal Muscle Development. During the 
initial stages of myogenesis, myoblast proliferation provides precursors for myofiber 
formation (PAX 7/MYF5 positive cells). Committed myoblasts (MYOD1 positive cells) 
stop proliferation and begin differentiation. Expression of myogenin promotes myoblast 
fusion for myotube formation, and MYF6 (aka MRF4) promote myotube maturation to 
form a myofiber. After maturation, myofibers begin hypertrophy which continues 











 After myofiber number is fixed,  fetal muscle growth continues through 
hypertrophy, which starts around the second half of pregnancy and remains as an active 
process postnatally. The study of Wei et al. (2014) found that myofiber area begins to 
increase around GD 85, which was caused by the addition of myonuclei between GD 85 
and 100. The same study found that myoblast proliferation was completed by GD 100, 
and followed by an increase in myofiber size likely due to intracellular protein 
deposition. Skeletal muscle hypertrophy through protein deposition is a very active 
process in the neonate and depends on the balance between rates of protein synthesis and 
degradation. Hypertrophy continues during postnatal life. Thus, alterations in myofiber 
size as a consequence of a prenatal stimuli have the potential to be corrected postnatally 
(Figure 1.3). 
5.2 Pathways for Skeletal Muscle Hypertrophy and Atrophy 
Protein deposition is essential for muscle growth and hypertrophy (Yao et al., 
2008) and is dependent upon an increase in the net balance of protein synthesis and 
protein degradation (Brown, 2014). Several molecular pathways interact to control 
protein synthesis and degradation in skeletal muscle, and most of them respond to 













Figure 1.3 Developmental Window of Sensitivity for Skeletal Muscle. The concept, 
window of sensitivity, refers to the time during gestation in which an organ is 
susceptible to influence from external stimuli. In skeletal muscle, stages of active 
myofiber formation (primary and secondary myogenesis) occur primarily during early 
and mid-gestation. If an insult such as nutrient restriction is applied during this time, it is 
expected to impair myofiber formation. In contrast, if nutrient restriction occurs in late 
gestation, it is more likely to affect myofiber hypertrophy and not number, because the 
peak time for myofiber formation has already passed. GD (Gestational day). Used with 








IGF1 - Insulin/PI3K/AKT1 Pathway 
 Insulin like growth factor 1 (IGF1) is an anabolic factor, which is particularly 
relevant to promote the growth of placental and fetal tissues, including skeletal muscle 
(Fowden, 2003).  IGF1 signaling is initiated by binding to the IGF1 receptor (IGF1R), 
which leads to the phosphorylation of insulin receptor substrate 1 (IRS1) (Egerman and 
Glass, 2014). Insulin acts as an anabolic hormone in addition to its role in glucose 
metabolism. Binding of insulin to insulin receptor (INSR) leads to phosphorylation of 
IRS1, and activation of downstream targets that are common for both, IGF1 and insulin 
signaling. Both insulin and IGF1 can bind to either IGF1R or INSR to activate this 
signaling pathway, but with greater affinity for their respective receptor (Belfiore et al., 
2009). 
  Activation of IRS1 will subsequently induce activation of phosphatidylinositol-
4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) (aka PI3K) which will 
finally phosphorylate and activate AKT serine/threonine kinase 1 (AKT1) (aka AKT). 
Activation of AKT1 is one of the regulatory factors for MTOR complex 1 (aka 
mTORC1) which induces protein translation and hence, has a profound impact in 
skeletal muscle hypertrophy (Rommel et al., 2001). Additionally, active AKT1 blocks 
the activity of forkhead box (FOXO) transcription factors. This leads to reduced 
expression of ubiquitin ligases, decreasing protein degradation in skeletal muscle. As a 
result of a stimulatory effect on protein synthesis, and inhibitory effect on protein 
degradation, the activation of AKT1 leads to increased protein deposition in skeletal 




MTOR Pathway  
 Mechanistic target of rapamycin (MTOR) signaling pathway includes both, 
MTOR complex 1 (previously known as mTORC1) and MTOR complex 2. MTOR 
complex 1 is involved in the regulation of protein synthesis and deposition to promote 
skeletal muscle hypertrophy. MTOR complex 2 is primarily involved in the promotion 
of cell proliferation (Wu, 2013a). MTOR complex 1 is associated to regulatory 
associated protein of MTOR complex 1 (RPTOR) (previously known as RAPTOR) 
(Kim et al., 2002) and is activated by phosphorylation of its serine 2448 residue, whose 
stimulation depends on the energy status of the cell and its nutrient availability. Insulin, 
IGF1, AKT1, and amino acids such as leucine and arginine have a stimulatory effect on 
MTOR complex 1 activity (Yoon, 2017). Particularly, the effect of amino acids has been 
related to translocation of MTOR complex 1 to the lysosome, where it comes in close 
proximity to the activator protein Ras homolog, mTORC1 binding (RHEB) (Saxton and 
Sabatini, 2017). In contrast, the activity of MTOR complex 1 is inhibited by 
glucocorticoids (Shimizu et al., 2011), protein kinase AMP-activated catalytic subunit 
alpha 2AMP-dependent kinase (PRKAA2) (aka AMPK), and myostatin (Rodriguez et 
al., 2014). 
 When active, MTOR complex 1 phosphorylates two proteins, ribosomal protein 
S6 kinase B1 (RPS6KB1) (aka S6K1) and eukaryotic translation initiation factor 4E 
binding protein 1 (EIF4EBP1) which is a translational repressor factor. Phosphorylation 




translation and protein synthesis. Phosphorylation of EIF4EBP1 leads to the inactivation 
of this protein, thus preventing its translational repressor effect (Wu, 2013a). 
Myostatin Pathway 
 Myostatin, a member of the transforming growth factor beta (TGFB) family, 
is a primary negative regulator of muscle hypertrophy (Rodriguez et al., 2014). This 
signaling pathway is mediated by binding of myostatin to serine/threonine receptors 
that activate SMAD family member 2 (SMAD2) and SMAD family member 3 
(SMAD3) by phosphorylation. SMAD 2,3 form a complex with SMAD family 
member 4 (SMAD4).  The complex is then translocated to the nucleus and controls 
the transcription of target genes involved in the inhibition of muscle hypertrophy  
(Trendelenburg et al., 2009).  Myostatin also inhibits the expression and 
phosphorylation of AKT1, which is involved in the activation of MTOR complex 1 
pathway for protein deposition (Morissette et al., 2009). 
 Other authors suggest that myostatin plays a role to inhibit myoblast 
proliferation, having the potential to affect myofiber number by decreasing 
hyperplasia during skeletal muscle development (Joulia et al., 2003). It has also been 
suggested that myostatin can upregulate E3 ubiquitin ligases to induce protein 
degradation (Lokireddy et al., 2011), but this effect is less well established (Egerman 
and Glass, 2014).  
Glucocorticoid-Mediated Atrophy Pathways 
 Protein deposition depends on both protein synthesis and degradation. Thus, the 




Decreased fetal muscle weight has been associated with lower protein synthesis and 
downregulation in the MTOR pathway (Zhu et al., 2004). However, makers for protein 
degradation have been found to be upregulated in skeletal muscle of chronically 
hypoglycemic fetuses, without alterations in pathways for protein synthesis (Brown et 
al., 2014). Hence it has been suggested that a decrease in muscle growth at the fetal stage 
may be the result of upregulation in pathways for muscle atrophy (Brown, 2014). 
 Glucocorticoids are involved in the regulation of energy homeostasis and play a 
role in controlling protein, carbohydrate, and fatty acid metabolism in skeletal muscle 
(Yoon et al., 2017). Different conditions increase the level of circulating glucocorticoids, 
such as severe deficit of insulin, sepsis, and starvation (Braun and Marks, 2015). 
Overall, these conditions represent a status of stress and nutrient deficiency in the 
organism in which catabolic processes are predominant. Accordingly, glucocorticoids 
have been recognized as activators of muscle atrophy (Menconi et al., 2007). 
 The study of Shimizu et al. (2011) found that binding of glucocorticoids to 
glucocorticoid receptor (NR3C1) inhibits the activity of MTOR complex 1 and 
stimulates muscle atrophy by upregulating expression of the starvation-sensitive 
transcription factor Kruppel like factor 15 (KLF15). KLF15 was found to upregulate 
expression of the mitochondrial isoform of the enzyme branched-chain amino acid 
transaminase 2 (BCAT2). This enzyme mediates the first step in branched-chain amino 
acid catabolism in skeletal muscle, which would decrease the availability of leucine, a 
branched-chain amino acid that has a stimulatory effect on MTOR complex 1 activity 




 Upregulation of KLF15 is also involved in the induction of a metabolic shift 
from glucose to fatty acid oxidation in skeletal muscle and muscle-liver cross-talk to 
support gluconeogenesis. These effects will be discussed later in this chapter.  
  Upregulation of KLF15, in response to glucocorticoids, was also shown to 
increase the expression of the ubiquitin ligases F-box protein 32 (FBXO32) (aka Atrogin 
1) and tripartite motif containing 63 (TRIM63) (aka MURF-1) (Shimizu et al., 2011). 
Other authors have also observed an upregulation of these ubiquitin ligases in response 
to glucocorticoids (Wray et al., 2003). FBXO32 and TRIM63 are involved in the 
proteasomal-mediated protein degradation system, where the majority of muscle proteins 
are degraded (Sandri, 2013). Inhibition of MTOR complex 1 activity has also been 
associated with upregulation of FBXO32 and TRIM63, which is indicative of both, 







Figure 1.4 Major Regulatory Pathways in Skeletal Muscle Protein Deposition. 
Protein deposition depends on the rate of protein synthesis and degradation. Pathways 
that stimulate protein synthesis in skeletal muscle are shown in blue. Amino acids 
(primarily the branched-chain amino acid leucine, and arginine) induce translocation of 
MTOR complex 1 to the lysosome, where the complex is activated by RHEB. TSC has 
inhibitory activity over RHEB. Insulin and IGF1 activate AKT1, which activates RHEB 
by inducing its separation from the inhibitory factor TSC. Pathways that inhibit protein 
synthesis or stimulate protein degradation are shown in orange. Myostatin inhibits 
MTOR through inactivation of AKT1. Glucocorticoids bind to their receptor (NR3C1) to 
induce expression of KLF15. It is suggested that this decreases activation of MTOR 
through increased breakdown of branched-chain amino acids (BCAA) via BCAT2. 
KFL15 upregulation would also increase protein degradation through upregulation of the 
ubiquitin ligases FBXO32 and TRIM63. PRKAA2 (aka AMPK) also has an inhibitory 
effect on MTOR when AMP is increased in the cell (not shown) (Based on data from 







Role of Apoptosis in Skeletal Muscle Atrophy 
 Apoptosis refers to programmed cell death, and while it is typically associated 
with disease stages, it plays an active role in healthy tissues undergoing fast proliferation 
or remodeling (Dupont-Versteegden, 2006) and is essential for normal development 
during the embryonic and fetal stage (Brill et al., 1999).  
 Different molecular pathways can trigger apoptosis, but in skeletal muscle, the 
BCL2 apoptosis regulator (BCL2) - BCL2 associated X (BAX) system has been found to 
be a primary pathway involved in this process (Sandri and Carraro, 1999). The BCL2 
family includes anti-apoptotic proteins, such as BCL2 itself, and proapoptotic factors 
such as BAX. The transcription factor tumor protein 53 (TP53) (aka p53) has 
proapoptotic action through induction of BAX expression without upregulation of the 
anti-apoptotic proteins of BCL2 family (Nicholson, 1999). Interestingly, results from 
mouse models suggest that in addition to its role in apoptosis, BCL2 is also required for 
normal muscle development (Dominov et al., 2001) which may lead to difficulty in 
interpretation of findings when measured at the fetal stage. 
 Most of the research in skeletal muscle has focused on apoptosis in postnatal 
disease models, creating a gap in knowledge regarding the role of apoptosis in normal 
skeletal muscle development, and in response to different stimuli that may alter the 
intrauterine environment (Sandri et al., 2001). However, indicators of increased 
apoptosis in response to nutrient restriction have already been reported in placenta 
(Belkacemi et al., 2009), fetal ovaries (Lea et al., 2006), and fetal kidney (Pham et al., 




  For skeletal muscle, one of the few studies conducted in fetal tissue found at least 
two waves of apoptosis during myogenesis in human muscle. One of them occurred in 
early myogenesis with the apparent purpose of removing excess cells to control the 
number of myofibers formed. The second wave occurred by mid-pregnancy, and its 
purpose appeared to be the acquisition of final myofiber size and shape (Fidziañska, 
1996). The study of Fidziañska (1996) did not provide information regarding apoptosis 
in fetal skeletal muscles in later stages of the pregnancy. Thus, the potential existence of 
additional waves of apoptosis remains unknown.  
 Several authors have described upregulation of apoptosis in postnatal skeletal 
muscle atrophy (Allen et al., 1999; Whitman et al., 2005). This is supported by the 
myonuclear domain hypothesis, which suggests that each myonucleus is able to support 
a specific amount of cytoplasm. Addition of nuclei during muscle development, or 
regeneration, allow for an increase in myofiber cytoplasm (Rosenblatt et al., 1994), 
while in atrophy, a loss of myonuclei reduces the cytoplasm that can be supported in 
certain myofiber. Apoptosis has been suggested as the mechanism responsible for the 
exclusion of nuclei during atrophy. This would lead to decreased cytoplasm, and 
myofiber size, without the death of the cell (Hikida et al., 1997) because apoptotic and 
normal myonuclei have been observed to coexist within the same myofiber.  
5.3 Myofiber Type Composition 
Skeletal muscle is composed of a mosaic of myofiber types with different 
metabolic characteristics. The most general classification of myofibers divides them 




during primary myogenesis are primarily type I, while type II myofibers are mainly 
formed during secondary myogenesis (Maltin, 2008). Myosin heavy chain (MYH) is 
specific for type I and type II myofibers. However, there is plasticity in regard to 
myofiber type as interconversion between type I and IIA myofibers, and between type 
IIA and IIB myofibers have been described (Picard, 2002; Maltin, 2008) (Figure 1.5).  
During muscle development, embryonic and fetal isoforms of MYH are expressed and 
later replaced by adult isoforms near term or postnatally. In altricial species, the 
expression of the adult MYH isoform occurs in late gestation, specifically around 
GD140 in the sheep (Finkelstein et al., 1992).  
Type I myofibers have a high mitochondrial dotation, elevated oxidative 
capacity and high insulin sensitivity, while type II myofibers have fewer mitochondria, 
lower oxidative capacity, low insulin sensitivity, and are primarily glycolytic (He et 
al., 2001). Within type II myofibers, type IIA and IIB are the major subtypes, and the 
most abundant in sheep longissimus dorsi muscle (Peinado et al., 2004). Type IIA 
myofibers are oxidative-glycolytic, which means that they show intermediate 
oxidative capacity, while type IIB are strongly glycolytic. Given these differences 
among myofiber types, the proportion of type I versus type II myofibers is an 










Figure 1.5 Myofiber Type Determination During Myogenesis. Primary myogenesis 
accounts for a fewer number of myofibers than secondary myogenesis, and those are 
primarily type I myofibers. Type I and type II myofibers are produced in secondary 
myogenesis. There is an interconversion potential between the myofibers that are closer 
in metabolic characteristics (Type I to type IIa, and type IIa to type IIb and vice versa). 
Plasticity of myofibers for interconversion is maintained postnatally. Reprinted with 









6. Overview of Skeletal Muscle Impact in Whole-Body Metabolism 
 Skeletal muscle plays an essential role in locomotion and structural support, but 
it is also involved in several functions that regulate energy metabolism. Examples of 
these functions are the capacity for oxidation of fatty acids, glucose, and some amino 
acids, storage of glycogen (Argilés et al., 2016), and support of gluconeogenesis in liver 
and kidney through the release of the amino acids, alanine and glutamine (Marliss et al., 
1971; Garber et al., 1976) which are synthesized in muscle using BCAA and α-
ketoglutarate as precursors (Wu, 2013b). Skeletal muscle is essential in the regulation of 
glucose metabolism because about 80% of insulin-induced glucose uptake occurs in this 
tissue (Ferrannini et al., 1985; DeFronzo and Tripathy, 2009). Because skeletal muscle 
represents 40% of body mass in adult organisms (Janssen et al., 2000), any alteration in 
muscle mass or metabolism will significantly impact whole-body metabolism (Brown, 
2014). As an example, it has been shown that insulin resistance at the skeletal muscle 
level is one of the primary metabolic alterations leading to type 2 diabetes in humans 
(DeFronzo and Tripathy, 2009). 
 Solute carrier family 2 member 4 (SLC2A4) (aka GLUT4) is the major glucose 
transporter in skeletal muscle, and its action is insulin dependent. The abundance and 
activity of this transporter are essential for insulin-mediated glucose uptake (Scheepers 
et al., 2004). SLC2A4 proteins are stored in cytoplasmic vesicles and translocated to the 
plasma membrane in response to insulin stimulation. Once in the membrane, glucose is 




 Translocation of SLC2A4 is induced by activation of the PI3K/AKT1 pathway 
after binding of insulin to its receptor (INSR) (Kohn et al., 1996). IGF1 can also trigger 
the activation of this pathway by binding to its receptor or to INSR (Mora et al., 1995; 
Alessi et al., 1996; Belfiore et al., 2009). This leads to phosphorylation of IRS1, and 
activation of PIK3CA (aka PI3K) which leads to activation of AKT1. Once active, 
AKT1 phosphorylates TBC1 domain family member 4 (TBC1D4) (aka AS160), to 
induce the translocation of SLC2A4 from the cytoplasm to the sarcolemma (Figure 1.6) 
(Taniguchi et al., 2006). Muscle contraction can also stimulate SLC2A4 translocation, 
which becomes relevant during postnatal life (Gao et al., 1994). 
 Upregulation of SLC2A4 in skeletal muscle begins late in fetal life and continues 
postnatally when this glucose transporter reaches maximum functionality (Stuart et al., 
2000). Solute carrier family 2 member 1 (SLC2A1) (aka GLUT1) is a ubiquitous 
glucose transporter whose action is not dependent on insulin, but directly in response to 
glucose concentration instead. This glucose transporter plays a major role during 




















Figure 1.6 Insulin-mediated SLC2A4 Translocation. Around 80% of insulin-mediated 
glucose uptake occurs in skeletal muscle. Insulin binds to its receptor (INSR) to activate 
the downstream target AKT1, which will activate TBC1D4 to induce SLC2A4 
translocation from cytoplasmic vesicles to the sarcolemma. Because of a high level of 
homology, IGF1 can also activate this pathway through its receptor (IGF1R) or binding 








Another factor that influences the metabolic characteristics of skeletal muscle 
is myofiber type composition, which impacts glucose metabolism and fatty acid 
oxidation. Type I myofibers are primarily oxidative and more sensitive to insulin than 
type II myofibers. Thus, its proportion shows a positive correlation with fatty acids 
and glucose oxidation, and with insulin-mediated glucose transport and whole-body 
insulin sensitivity (Lillioja et al., 1987; Fisher et al., 2017). 
 The ability of skeletal muscle to oxidize fatty acids provides metabolic plasticity 
under conditions such as starvation or exercise, which spares glucose for tissues that 
depend primarily on this energy source.  KLF15, a transcription factor expressed 
primarily in skeletal muscle and adipose tissue, but also in liver, acts as a starvation 
sensor and has a major role regulating whole-body metabolism (Gray et al., 2007; Haldar 
et al., 2012). One of its effects is to induce a metabolic switch from glucose oxidation to 
fatty acid oxidation in response to fasting (Takeuchi et al., 2016). A suggested 
mechanism mediating this role is the upregulation of mitochondrial acetyl-CoA 
synthetase, which synthesizes acetyl-CoA for mitochondrial oxidation (Yamamoto et al., 
2004). 
 It has also been described that KLF15 upregulates hepatic gluconeogenesis under 
starvation conditions.  A suggested mechanism for this function is an increase in BCAT2 
transcription in skeletal muscle (Gray et al., 2007). BCAT2 is a mitochondrial enzyme 
involved in branched-chain amino acid (BCAA) transamination in muscle. Skeletal 
muscle can synthesize alanine from BCAA and release it into the circulation to be taken 




between muscle and liver is relevant to maintain euglycemia under starvation conditions, 
and the regulatory role of KLF15 in this process has been described during postnatal life 
(Fan et al., 2018). However, to our knowledge, it has not been determined if the 
starvation sensor function of KLF15 is already active during fetal development. 
7. Effect of Maternal Nutrient Restriction in Fetal Skeletal Muscle Growth 
and Metabolism 
 During fetal development, tissues have different priorities regarding nutrient 
partitioning, so that under severe maternal nutrient restriction, growth and development 
of vital organs such as the brain and heart will be prioritized over non-vital tissues, such 
as skeletal muscle (Desai et al., 1996). As a consequence, fetal skeletal muscle 
development is highly susceptible to nutritional insults. 
 Because of the developmental timing of fetal skeletal muscle, myogenesis is 
expected to be altered in response to nutritional insults during early to mid-gestation, 
while alterations in myofiber hypertrophy are primarily expected from mid to late 
gestation. A peri-conception treatment of 50% NR applied from 18 days before 
ovulation to 6 days after ovulation found a tendency for decreased myofiber number in 
sheep semitendinosus muscle at GD 75 (Quigley et al., 2005). Muscle weight and 
myofiber cross-sectional area were not affected in this study. This was expected given 
that the NR insult was not applied during the window of sensitivity for myofiber 
hypertrophy. 
 A sheep model of 50% NR between GD 28 and 78 found a decrease in the 




associated with impaired myoblast proliferation during secondary myogenesis (Zhu et 
al., 2004), a process that begins around GD 62 in the sheep (Maltin, 2008). The study of 
Zhu et al. (2004) also found a decrease in myofiber area in longissimus dorsi of fetuses 
from NR dams. This finding was associated with a reduction in MTOR and RPS6KB1 
protein phosphorylation without upregulation in ubiquitin-labeled proteins. These results 
were indicative of decreased protein synthesis in the absence of evidence for increased 
protein degradation.  
 In a later study from the same group, lambs were naturally delivered after 50% 
NR between GD 28 and 78 and fed ad libitum until eight months of age. At this time, 
longissimus dorsi was collected, and no differences in myofiber hypertrophy or muscle 
weight were found (Zhu et al., 2006). Another model of 50% NR from GD 85 to 115 
found a decrease in weight of longissimus dorsi in 14-day-old lambs (Fahey et al., 2005). 
Collectively these findings support the fact that nutritional alterations in early prenatal 
life affect myogenesis, while nutritional restriction during mid or late pregnancy 
primarily affects myofiber hypertrophy. This last effect can be partially compensated 
after birth because muscle hypertrophy continues during postnatal life, and neonates 
experience accelerated rates of protein deposition when nutrients are available (Rudar et 
al., 2019). 
 Decreased fetal growth after prenatal nutrient restriction is usually followed by 
compensatory growth during postnatal life (De Blasio et al., 2007) However, in the long 
term, this compensatory growth will favor adipose tissue deposition instead of muscle 




from GD 28 to 78 were heavier than controls, had increased renal and pelvic adipose 
tissue, and a tendency for decreased weight in longissimus dorsi and semitendinosus 
muscles. This study also found evidence of hyperglycemia and altered insulin secretion 
after a glucose tolerance test (Ford et al., 2007). Accordingly, 1-year-old offspring born 
to sheep under 50% NR from GD 110 to term, showed evidence of glucose intolerance 
as indicated by increased areas under the curve for glucose and insulin (Gardner et al., 
2005). 
 Indicators of alterations in glucose and insulin metabolism have been found in 
skeletal muscle at the fetal stage after maternal nutrient restriction. A sheep model of 
50% NR from GD 104 to 127 produced upregulation of SLC2A4, INSR, and IGF1 
mRNA in fetal triceps brachii muscle at GD127 (Costello et al., 2008). These results 
suggest a metabolic programming effect that could be partly responsible for the 
compensatory growth that SGA animals experience early in postnatal life. The authors 
also suggested that an initial upregulation in insulin receptor may play a role in the 
development of metabolic diseases later in postnatal life (Costello et al., 2008). 
Supporting data was provided by a study that induced 70% NR from GD 0 to 6 in sheep. 
This treatment was found to upregulate IRS1 and SLC2A4 mRNA expression in 
quadriceps muscle at GD 137±1 (Lie et al., 2014). 
 The study of Costello et al. (2008) also measured myofiber and capillary density 
and compared triceps brachii and soleus muscles for this analysis. Decreased myofiber 
and capillary density were found in the triceps brachii, but not in the soleus. A possible 




has a higher proportion of type II myofibers and the soleus is primarily type I.  Most 
type I myofibers are formed in early gestation (primary myogenesis), so they may 
remain unaltered when the NR treatment is applied outside the window of sensitivity. 
Soleus muscle has also been identified by other investigators as relatively resistant to 
maternal nutrient restriction (Ward and Stickland, 1991). These results indicate that 
regardless of having been exposed to the same treatment, a muscle-specific response can 
occur.  
 Maternal nutrient restriction has also been shown to alter myofiber type 
composition in skeletal muscle. A 50% NR from GD 28 to GD 78 has been associated 
with increased content of type IIb myofibers in longissimus dorsi of 8-month-old lambs 
(Zhu et al., 2006). This study also found decreased activity of the enzyme carnitine 
palmitoyltransferase-1, which is involved in fatty acid oxidation, and accordingly, 
intramuscular triglyceride (IMTG) content was increased. These findings suggest 
metabolic programming in skeletal muscle which would impair oxidative capacity and 
insulin sensitivity, as type II myofibers are primarily glycolytic and less insulin sensitive 
than type I myofibers (He et al., 2001). Accumulation of IMTG has also been recognized 
as a cause for disruption in insulin signaling, and insulin resistance in skeletal muscle 
(Corcoran et al., 2007). 
  Contradictory results have been found in longissimus dorsi of 14-day-old lambs 
in which an increase in type I myofibers was found after 50% NR from GD 30 to 70 
(Fahey et al., 2005). The difference in offspring age at which these two studies were 




(2006) are supported by the study of Costello et al. (2008), in which a sheep model of 
50% NR from GD 104 to 127 was shown to reduce type I myofiber content in fetal 
triceps brachii muscle at GD127. Myofiber type composition conserves a certain level of 
plasticity during postnatal life in response to some stimuli such as exercise. Thus, more 
research is needed to confirm the long-lasting effect of myofiber type programming 
during fetal development (Brown, 2014). 
 The discussed data supports the existence of a programming effect on fetal 
myofiber formation, skeletal muscle mass, metabolism, and myofiber composition in 
response to maternal nutrient restriction. Nevertheless, while available studies have 
typically considered fetuses within NR treatments as a single experimental group, 
preliminary results from our laboratory have routinely shown an ample variation of fetal 
weights in response to NR in the sheep. Thus, studies were conducted to evaluate the 
effect of maternal NR on fetal skeletal muscle growth and metabolism while accounting 





CHAPTER II                                                                                                                
EFFECT OF MATERNAL NUTRIENT RESTRICTION ON PATHWAYS FOR 
FETAL SKELETAL MUSCLE GROWTH IN SGA AND NON-SGA SHEEP 
FETUSES                                                                                                                                                                                      
 
1. Introduction 
Maternal nutrient restriction (NR) during pregnancy is a cause for small for 
gestational age (SGA) offspring, which exhibit a greater risk to develop metabolic 
syndrome in adulthood (Barker and Clark, 1997; Ozzane et al., 1999). Several fetal 
organs can be affected by maternal NR (Osgerby et al., 2002; Vonnahme et al., 2003; 
Lloyd et al., 2012; Satterfield et al., 2013), but skeletal muscle is among the most 
susceptible ones because of nutrient prioritization to vital organs (Desai et al., 1996). 
SGA offspring have typically been associated with decreased muscle mass caused by 
reduced myofiber number (Quigley et al., 2005), impaired hypertrophy (Fahey et al., 
2005), or both (Zhu et al., 2004). 
Skeletal muscle plays an essential role in the regulation of oxidative and glucose 
metabolism, as it represents about 40% of body mass in healthy individuals (Janssen et 
al., 2000), and roughly 80% of insulin-mediated glucose uptake occurs in this tissue 
(Ferrannini et al., 1985). Thus, a decrease in muscle mass leads to an unhealthy 
phenotype that is itself a predisposition for metabolic alterations (Kensara et al., 2005; 
Atlantis et al., 2009). Additionally, in an agricultural context, decreased muscle mass in 




producers, and decreasing the production of protein for human consumption, which 
further impacts human health (Wu et al., 2006). 
 During fetal development, myofiber formation (myogenesis) is an active process 
in early to mid-gestation (Maltin, 2008) and depends on myoblast proliferation and 
fusion. Muscle growth continues through hypertrophy in late gestation and postnatally, 
and it accounts for the major increase in muscle mass during late prenatal and postnatal 
stages (McCoard et al., 2001). Hence, impaired prenatal muscle hypertrophy has the 
potential to be compensated postnatally, but it has been demonstrated that reductions in 
muscle mass persist until late postnatal life in low-birth-weight humans (Kensara et al., 
2005). This is, in part, explained because SGA offspring typically experience accelerated 
postnatal growth, but this favors adipose tissue deposition instead of muscle (De Blasio 
et al., 2007). 
 Skeletal muscle hypertrophy depends upon protein synthesis and degradation. A 
major regulator of protein synthesis is mechanistic target of rapamycin (MTOR), which 
induces protein translation when active. The activity of this pathway relies on nutritional 
and energy availability and is activated by anabolic signals such as insulin and insulin 
like growth factor 1 (IGF1), and amino acids such as leucine and arginine (Yoon, 2017). 
Amino acids also act as building blocks for protein synthesis, so their availability is 
essential to support this process.  MTOR signaling is inhibited by negative regulators of 
muscle mass such as myostatin and glucocorticoids (Rodriguez et al., 2014; Braun and 
Marks, 2015). At the fetal stage, MTOR activity has been found to be downregulated in 




markers for protein degradation have been found to be upregulated in fetal muscles 
without modifications in pathways for protein synthesis in response to chronic glucose 
restriction during the last 40% of pregnancy (Brown et al., 2014). Accordingly, we have 
previously observed no differences in MTOR pathway activity in our sheep model of 
maternal NR at gestational day (GD) 125 (Keith et al., unpublished results). It has been 
suggested that upregulation on pathways for protein degradation, which typically 
mediate atrophy in adult muscles, may be upregulated in fetal muscles under maternal 
NR conditions and be the cause for decreased protein deposition (Brown and Hay, 
2016).  
 Glucocorticoids are a major negative regulator of protein deposition during 
muscle atrophy in adult tissues (Braun and Marks, 2015), but their action has also been 
demonstrated in fetal muscles (Gokulakrishnan et al., 2012). However, the regulation 
and effects of this pathway in fetal skeletal muscles have been less studied than in adult 
tissues (Brown et al., 2014), but it is of interest under altered physiologic conditions that 
would trigger muscle atrophy in adult tissues, such as undernutrition and cachexia. One 
pathway of glucocorticoid action is through upregulation of the starvation-sensitive 
factor Kruppel like factor 15 (KLF15). This factor upregulates the ubiquitin ligases F-
box protein 32 (FBXO32) and tripartite motif containing 63 (TRIM63), which are 
mediators of protein degradation, and indirectly inhibits MTOR through an increase in 
branched-chain amino acid breakdown (Shimizu et al., 2011). Additionally, KLF15 
orchestrate metabolic adaptations to protect glucose homeostasis during starvation (Gray 




maternal NR, and its potential effects at the fetal stage has not been evaluated, but given 
its starvation-sensitive characteristic, it is feasible that KLF15 is altered by prenatal 
nutrient scarcity. 
The majority of published studies describing decreased muscle weight and 
myofiber hypertrophy in response to maternal NR have focused on downregulation of 
pathways for decreased protein synthesis rather than upregulation in protein degradation.  
Further, studies have typically considered fetuses from NR dams as a single 
experimental group regardless of their growth rates. However, our studies in a NR sheep 
model have shown a spectral phenotype of fetal growth rates, possibly due to maternal 
adaptation to nutrient scarcity in order to support fetal growth.  Due to these 
observations, we sought to characterize mechanisms by which the placenta adapts to 
nutritional deprivation and the resultant fetal responses. This study aimed to evaluate the 
effect of differential responses to maternal NR on myofiber hypertrophy, the 
glucocorticoid-mediated pathway for muscle atrophy, and its interactions with MTOR 
activation. 
2. Materials and Methods 
All experimental procedures in this study were approved by the Institutional 
Agricultural Animal Care and Use Committee of Texas A&M University. 
2.1 Animal Handling and Tissue Collection 
Mature Hampshire ewes of similar frame size, parity, and body condition were 
fed to meet 100% of their nutritional requirements according to recommendations of the 




estrus synchronization and superovulation was administered to donor and recipient ewes. 
Hampshire donor ewes were artificially inseminated, and on gestational day (GD) 6, a 
single embryo was transferred from a donor ewe into the recipient uterus. Ultrasound 
was used as pregnancy diagnostic on GD 28. On GD 28, ewes were housed in individual 
pens on concrete and maintained in these conditions until GD 135. Ewes were fed once 
per day. Rations were adjusted once per week based on weekly measurements of body 
weight. On GD 35, ewes were randomly divided into a control-fed group which received 
100% NRC requirements, and a nutrient-restricted (NR) group, which received 50% of 
total NRC requirements. Composition of the diet has been published previously (Lassala 
et al., 2010). Necropsies were conducted on GD 135. At this time, blood samples from 
fetal umbilical vein and fetal heart were collected to obtain fetal plasma. Soleus and 
gastrocnemius muscles were dissected and weighed, and samples preserved for further 
investigation. 
Fetuses from ewes fed 100% NRC formed the Control group (n=12). Fetuses 
from NR ewes were divided into quartiles based on fetal weight distribution. The highest 
(NR(Non-SGA) group; n=11) and lowest (NR(SGA) group; n=11) quartiles were 
selected for further investigation (Keith et al., unpublished results). 
2.2 Immunofluorescence 
Immunofluorescence was used to measure myofiber area. One section of 8 µm 
was obtained per sample using a cryostat at -16oC. A modification of the protocol 
described by Wang et al. (2014) was used. Briefly, each section was fixed in cold 




temperature. After that, an anti-laminin antibody (1:300, catalog number L9393, Sigma, 
St. Louis, MO) was added for overnight incubation at 4°C. Rabbit IgG was substituted 
for the primary antibody as a negative control. A secondary antibody (1:500, Alexa 
Fluor 594®, Thermo Fisher Scientific, Waltham, MA) was then added for one hour of 
incubation at room temperature. Slides were overlaid using Prolong Antifade (Life 
Technologies, Carlsbad, CA) without DAPI. Eight non-overlapping areas were imaged 
per each section, using a Nikon Eclipse Ni-E fluorescence microscope and NIS-
Elements AR 4.30.02 64-bit Software (Nikon Instruments Inc., Melville, NY). For 
quantification, the cross-sectional area of 10 randomly selected cells was measured in 
each of the eight areas per sample and averaged to get a representative value. 
2.3 Cortisol Concentration in Fetal Plasma 
Cortisol concentration in plasma was measured using RIA  
(Catalog number CRCT-1000V-100/500, IVD Technologies, Orange County, CA) 
according to manufacturer recommendations. To calculate total hormone content in the 
fetal circulation concentrations were multiplied by blood volume, which was estimated 
at 110ml/kg fetal weight (Brace, 1983; Brace, 1986). 
2.4 Amino Acid Concentration and Total in Fetal Plasma 
Amino acid concentration in fetal plasma was measured as described by 
Satterfield et al. (2013). Briefly, fetal plasma samples were deproteinized, and amino 
acids content was measured using fluorimetric HPLC with precolumn derivatization 
using o-phthaldialdehyde. Chromatographic peaks were integrated using Millenium-32 




circulation, concentrations were multiplied by blood volume, which was estimated at 
110ml/kg fetal weight (Brace, 1983; Brace, 1986). 
2.5 RNA Extraction and qPCR  
Trizol (Gibco-BRL, Bethesda, MD) was used for RNA extractions. RNA 
quantity was assessed by spectrophotometry, and quality was evaluated based on RNA 
Integrity Number (RIN) after running the samples on a bioanalyzer. cDNA was made by 
reverse transcription using SuperScript II kit and oligo-dT primers (Invitrogen, Carlsbad, 
CA) by reverse PCR in an Eppendorf Mastercycler Nexus Thermal Cycler (Thermo 
Fisher Scientific, Waltham, MA). Newly synthesized cDNA was used to measure 
relative gene expression by qPCR using a 7900 HT fast real-time PCR system (Applied 
Biosystems, Foster City, CA).  SYBR Green (Applied Biosystems, Foster City, CA) was 
added as a detector and signals were integrated using SDS2.4 software. Primers were 
designed to quantify the expression of glucocorticoid receptor (NR3C1), Kruppel like 
factor 15 (KLF15), forkhead box O1 (FOXO1), F-box protein 32 (FBXO32), tripartite 
motif containing 63 (TRIM63), branched chain amino acid transaminase 2 (BCAT2), 
myostatin (MSTN), and lipoprotein lipase (LPL). EEF1A2 (gastrocnemius) or SF3A1 
(soleus) were used as housekeeping genes (Pérez et al., 2008) (Table 2.1). Relative 











Table 2.1 Primers Used for qPCR Analysis 1 
1Forward and Reverse Primers were designed using Primer-BLAST Tool from NCBI 
with the showed accession numbers as sequence input.  Primer sets having a citation 
instead of accession number were obtained from published articles. All primers were 
tested for specificity using BLAST tool from NCBI and dissociation curve analysis to 
confirm amplification of a single product. Standard curves were used to optimize the 

























































2.6 Protein Extraction and Western Blots 
Total protein from soleus and gastrocnemius muscles were extracted by tissue 
homogenization in lysis buffer using snap-frozen samples. Protein concentration was 
measured using Bradford protein assay (Bio-Rad Laboratories, Inc., Hercules, CA) using 
BSA as standard. Primary antibodies were purchased from Cell Signaling Technology 
(Danvers, MA). Total and phosphorylated FOXO1 (1:1000 catalog numbers 2880 and 
2486), MTOR (1:1000, catalog numbers 2972 and 2971), EIF4EBP1 (1:1000, catalog 
numbers 9452 and 9455), RPS6 (1:1000, catalog numbers 9202 and 9206), and 
MAPK3/MAPK1 (aka ERK1/2) (1:1000, catalog numbers 9102 and 9101) were 
quantified by western blots as previously described (Spencer et al., 1999) using 50 ug of 
protein. Total and phosphorylated MTOR proteins were transferred overnight at 4°C and 
30V, while all the other proteins were transferred at 100V for 1.5 hours in a cold 
chamber. An IgG-horseradish peroxidase-conjugated antibody (1:20000 of 1mg/ml 
stock) (KPL, Bethesda, MD) followed by incubation on SuperSignalTM West Dura 
(Thermo Scientific, Waltham, MA) were used to detect immunoreactive proteins by 
chemiluminescence. Proteins were quantified using Quantity One® 4.6.1 Software 
(Biorad Laboratories, Inc., Hercules, CA) with tubulin (1:10000, catalog number 
Ab8291, Abcam, Cambridge, MA) and GAPDH (1:10000, catalog number 2118, Cell 







2.7 Statistical Analysis 
Data were analyzed using JMP® Pro 14 software (SAS Institute Inc., Cary, NC). 
One-way ANOVA (α= 0.05) analysis was used to compare the means of control (n=12), 
NR(SGA) (n=11) and NR(non-SGA) (n=11) groups and differences between specific 
means were evaluated using Tukey’s test. 
3. Results 
3.1 Fetal and Muscle Weights 
Fetal weight at GD 135 was not different between the control and NR(Non-SGA) 
groups, while it was lower (P<0.0001) in the NR(SGA) group (Figure 2.1). Fetal 
muscle weights of both, gastrocnemius and soleus, followed the same pattern as there 
were no differences between control and NR(Non-SGA) groups, and both groups had a 






























Figure 2.1 Fetal Weights at GD 135 and Experimental Group Formation. 
(A)Weight distribution of fetuses from control (n=12) and nutrient restricted (NR) ewes 
(n=44). Highest quartile (grey closed circles) forms the NR(Non-SGA) group (n=11). 
Lowest quartile (grey open circles) forms NR(SGA) group (n=11). (B) Average fetal 
weights per group (X̅±SEM). Means without a common superscript between Control, 
























Figure 2.2 Fetal Muscle Weights at GD 135. Mean weight for gastrocnemius (A), and 
soleus (B) per group are shown as X̅±SEM. For both muscles, NR(SGA) fetuses had a 
lower mean weight than NR(Non-SGA) and controls. Means without a common 















3.2 Myofiber Cross-sectional Area 
For both, gastrocnemius and soleus muscles, average myofiber cross-sectional 
area was decreased (P=0.0068 and P=0.0070, respectively) in NR(SGA) group 
compared to control, while the NR(Non-SGA) group had intermediate values and were 
not different from either control or NR(SGA) groups (Table 2.2, Figure 2.3A and 2.3B). 
 
Table 2.2 Myofiber Cross-sectional Area per Group in Gastrocnemius and Soleus 
Muscles at GD 1351 
1Means represent measured areas within each muscle for Control, NR(Non-SGA), and 
NR(SGA) groups. Data is shown as X̅±SEM. Different superscripts indicate P<0.01. 




3.3 Cortisol Levels in Fetal Plasma 
  Neither cortisol concentration (µg/dL) (P=0.2026) nor estimated total cortisol 
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Figure 2.3 Myofiber Cross-Sectional Area in Gastrocnemius and Soleus Muscles at 
GD 135.  Immunoreactive protein for Laminin (Red) are shown for Gastrocnemius (A) 
and Soleus (B) in control, NR(Non-SGA), and NR(SGA) groups. Laminin was used as a 
plasma membrane marker to delineate myofiber cross-sectional area (CSA). Magnified 
pictures show details of CSA per group, showing smaller areas for myofibers in the 
NR(SGA) group. CSA quantifications are shown in Table 2.2. For the IgG control (not 
shown), normal rabbit IgG was substituted for the primary antibody. Pictures were taken 






3.4 Amino Acid Levels in Fetal Plasma 
Fetal plasma concentration of arginine (Arg), leucine (Leu), and total amino 
acids were higher (P<0.05) in NR(Non-SGA) compared to NR(SGA), while control 
group had an intermediate concentration and did not differ from the other two groups. 
Threonine (Thr) and β-alanine concentrations were lower (P<0.05) in NR(SGA) 
compared with control fetuses, while NR(Non-SGA) did not differ from the other two 
groups. Specific results for the concentration of each amino acid are shown in Table 
2.3). The total content in circulation of most individual amino acids, as well as total 
amino acids, were higher (P<0.05) in both, control and NR(Non-SGA) compared to the 
NR(SGA) group. Specific results for total content of each amino acid are shown in Table 
2.4. 
3.5 mRNA Expression  
Within gastrocnemius muscle, NR3C1 and FOXO1 were upregulated in 
NR(SGA) (P=0.0099 and P=0.0131, respectively) compared to control, while NR(Non-
SGA) did not differ from the other groups. KLF15 was upregulated in both, NR(Non-
SGA) (P=0.0178) and NR(SGA) (P=0.0001) compared to the control group. LPL was 
upregulated in both, NR(Non-SGA) (P=0.0289) and NR(SGA) (P=0.0330) compared to 
control.  No differences were found for FBXO32 (P=0.3387), TRIM63 (P=0.5647), 
BCAT2 (P=0.7631), or MSTN (P=0.3787) (Figure 2.5). Within soleus muscle, there was 
an upregulation of KLF15 in NR(SGA) group (P=0.0114) compared to control, while 
NR(Non-SGA) group did not differ from either control or NR(Non-SGA) groups. 




groups compared to control. MSTN was upregulated in NR(SGA) (0.0259) compared to 
control. No differences were found for NR3C1 (P=0.2888), FOXO1 (P=0.5559), 
FBXO32 (P=0.9808), TRIM63 (P=0.0615), or LPL (P=0.4569) (Figure 2.6). 
3.6 Protein Expression 
For gastrocnemius, there were no differences in the ratio between total and 
phosphorylated FOXO1 (P=0.7254), MTOR (P=0.7637), RPS6 (P=0.9003), EIF4EBP1 
(P=0.7884) and MAPK3/MAPK1 (P=0.4341). Similarly, for soleus, there were no 
differences in the ratio between total and phosphorylated FOXO1 (P=0.1978), MTOR 
(P=0.9029), RPS6 (P=0.9896), EIF4EBP1 (P=0.5976), and 
MAPK3/MAPK1(P=0.7907). For both muscles, there were no differences in either total 
or phosphorylated content of any of the evaluated proteins (P>0.05) (Figure 2.7 and 






























Figure 2.4 Cortisol Levels in Fetal Plasma at GD 135. Concentration and total levels 
of cortisol in control, NR(Non-SGA) and NR(SGA) are shown in (A) and (B) 
respectively. Data is shown as X̅±SEM. Means without a common superscript between 





Table 2.3 Amino Acid Concentration in Fetal Plasma at GD 1351 












Ala 408.4 ± 29.6 445.4 ± 29.6 329.5 ± 35 0.0661 
β-Ala 19.1 ± 1.9 a 13.8 ± 1.9 ab 6.9 ± 2.2 b 0.0031 
Arg 289.5 ± 30.9 ab 371.9 ± 30.9 a 207.7 ± 33.4 b 0.0080 
Asn 64 ± 4.3 ab 69.6 ± 4.3 a 50.9 ± 5.1 b 0.0427 
Asp 5.6 ± 0.9 6.8 ± 0.9 5.3 ± 1 0.5623 
Cit 214 ± 19.9 184.8 ± 19.9 147.1 ± 23.3 0.1268 
Gln 465.2 ± 60.7 552.1 ± 60.7 328.9 ± 71.9 0.0898 
Glu 114.1 ± 18.2 121.2 ± 18.2 117 ± 19.7 0.9633 
Gly 351.8 ± 53.9 425.9 ± 53.9 390.5 ± 63.8 0.6323 
His 32.5 ± 4.0 36.2 ± 4 29.1 ± 4.7 0.5368 
Ile 66.4 ± 6.5 84.1 ± 6.5 66.8 ± 7.4 0.1183 
Leu 127.5 ± 8.3 ab 157.2 ± 8.3 a 123 ± 9 b 0.0226 
Lys 132 ± 13.2 163.8 ± 13.2 126.5 ± 14.2 0.1374 
Met 30.2 ± 3.1 29.8 ± 3.1 27 ± 3.4 0.7655 
Orn 193.1 ± 22.1 185.4 ± 22.1 155.9 ± 26.2 0.5463 
Phe 86.5 ± 7.1 99.1 ± 7.1 94.6 ± 7.7 0.0556 
Ser 597 ± 68.5 686.3 ± 68.5 489.3 ± 74 0.1791 
Tau 154.9 ± 30.7 139.1 ± 30.7 142.5 ± 33.1 0.9302 
Thr 285.8 ± 34 a 246.2 ± 34 ab 136.8 ± 40.3 b 0.0361 
Trp 75.6 ± 3.6 77.7 ± 3.6 76.6 ± 3.9 0.6568 
Tyr 74.7 ± 4.6 75.7 ± 4.6 73 ± 5 0.9245 
Val 187.3 ± 12.1 213.1 ± 12.1 194.8 ± 13.9 0.3300 




Table 2.4 Total Content of Amino Acids in Fetal Blood at GD 1351 














Ala 250.7 ± 16.8 a 267.1 ± 16.8 a 138.8 ± 19.8 b 0.0003 
B-Ala 11.8 ± 1.1 a 8.3 ± 1.1 a 2.84 ± 1.4 b 0.0031 
Arg 179.1 ± 18.7 a 224 ± 18.7 a 87.6 ± 20.2 b 0.0005 
Asn 39.6 ± 2.8 a 41.8 ± 2.8 a 21.3 ± 3.3 b 0.0026 
Asp 3.5 ± 0.5 4 ± 0.5 2.2 ± 0.6 0.1353 
Cit 132.7 ± 11.8 a 111 ± 11.8 a 59.8 ± 14 b 0.0038 
Gln 289.6 ± 36.1 a 333.1 ± 36.1 a 135.2 ± 42 b 0.0080 
Glu 70 ± 9.9 72.2 ± 8.8 43.1 ± 11.7 0.2261 
Gly 217.7 ± 31  256.3 ± 31  157 ± 36.7 0.1512 
His 20.2 ± 2.4 21.6 ± 2.4  12.1 ± 2 0.0520 
Ile 41.2 ± 4 ab 50.5 ± 4 a 27.3 ± 4.8 b 0.0075 
Leu 78.9 ± 5.2 a 94.3 ± 5.2 a 51.2 ± 5.6 b 0.0001 
Lys 81.7 ± 6.9 a 98.3 ± 6.9 a 52.5 ± 7.5 b 0.0013 
Met 18.5 ± 1.6 a 17.9 ± 1.6 a 10.2 ± 1.8 b 0.0073 
Orn 118.7 ± 13.1 a 111.2 ± 13.1 ab 65.9 ± 15.5 b 0.0468 
Phe 47.9 ± 3.32 ab 59.4 ± 3.07 a 39.2 ± 3.32 b 0.0015 
Ser 367.7 ± 39.7 a 413.1 ± 39.7 a 201.2 ± 42.9 b 0.0057 
Tau 94.1 ± 16.3 82.9 ± 16.3 61.7 ± 17.6 0.4169 
Thr 178 ± 21.1 a 147.2 ± 21.1 a 57 ± 25 b 0.0063 
Trp 46.9 ± 2.7 a 46.7 ± 2.7 a 30.7 ± 3.28 b 0.0026 
Tyr 46.4 ± 2.9 a 45.4 ± 2.9 a 30.1 ± 3.1 b 0.0027 
Val 115.9 ± 7.4 a 127.8 ± 7.4 a 81.1 ± 7.9 b 0.0015 










Figure 2.5 mRNA Expression in Gastrocnemius at GD 135. Relative mRNA 
expression for NR3C1(A), KLF15 (B), FOXO1 (C), TRIM63 (D), FBXO32 (E), BCAT2 
(F), LPL (G), and MSTN (H) are shown. Data is shown as X̅±SEM. Means without a 









Figure 2.6 mRNA Expression in Soleus at GD 135. Relative mRNA expression for 
NR3C1(A), KLF15 (B), FOXO1 (C), TRIM63 (D), FBXO32 (E), BCAT2 (F), LPL (G), 
and MSTN (H) are shown. Data is shown as X̅±SEM. Means without a common 












Figure 2.7 Protein Levels in Gastrocnemius at GD 135. Ratios between 
phosphorylated and total FOXO1 (A), MTOR (B), RPS6K (C), EIF4EBP1 (D), and 
MAPK3/1 (E) are shown. Data is shown as X̅±SEM. Means without a common 
superscript between Control, NR(Non-SGA), and NR(SGA) differ (P<0.05).  Individual 
phosphorylated and total protein levels were not different for any of the target proteins 










Figure 2.8 Protein Levels in Soleus at GD 135. Ratios between phosphorylated and 
total FOXO1 (A), MTOR (B), RPS6K (C), EIF4EBP1 (D), and MAPK3/1 (E) are 
shown. Data is shown as X̅±SEM. Means without a common superscript between 
Control, NR(Non-SGA), and NR(SGA) differ (P<0.05).  Individual phosphorylated and 






The objective of this study was to evaluate the effect of differential responses to 
maternal NR on myofiber hypertrophy, glucocorticoid-mediated pathways for protein 
degradation, and its interactions with MTOR activation. These factors are determinants 
of fetal skeletal muscle growth, which if impaired, is associated with a greater 
predisposition to metabolic dysregulation in aged offspring. From an agricultural 
perspective, decreased lean mass in livestock species would negatively impact animal 
protein production, which would further affect human nutrition and health. Results 
highlight an absence of differences in pathways for protein synthesis and degradation in 
skeletal muscle, but enhanced availability of amino acids in the NR(Non-SGA) group, 
likely suggesting a unique materno-placental mechanism for amino acid transport in this 
group. This would support a higher rate of protein synthesis in the NR(Non-SGA) group 
and a suboptimal response in NR(SGA) fetuses likely due to lower precursor 
availability. 
Several studies have previously described that fetal weight and skeletal muscle 
mass are decreased by maternal NR (Osgerby et al., 2002; Kwon et al., 2004; Fahey et 
al., 2005, Satterfield et al., 2009). Here we confirm our previous results of unequal 
alterations in fetal weight in response to our sheep model of maternal NR, as we 
continuously identify two phenotypes for fetal weight within the NR group, namely 
NR(SGA) and NR(Non-SGA). Likewise, we found that maternal NR does not 
necessarily impair skeletal muscle mass, as we have found reduced muscle weight in the 




exposure to the same prenatal treatment. However, for both muscles, myofiber sectional 
area was decreased in the NR(SGA) group compared to control but did not differ 
between NR(SGA) and NR(Non-SGA), with NR(Non-SGA) exhibiting an intermediate 
phenotype. These results indicate that alterations in myofiber hypertrophy do not 
completely explain the observed differences in muscle weight between NR(SGA) and 
NR(Non-SGA) groups. 
Hypertrophy begins around GD 100 in the sheep (McCoard et al., 2001, Wei et 
al., 2014), and while it accounts for the majority of the increase in muscle mass, the 
maximum growth potential of this tissue is limited by myofiber number (Brown, 2014). 
Myofiber formation occurs in two main waves, primary myogenesis starting by GD 32 
and secondary myogenesis starting by GD 65 in sheep (Maltin, 2008). Thus, our NR 
treatment from GD 35 to GD 135 would likely affect myofiber formation. A potential 
lower number of myofibers, in addition to decreased myofiber area, may explain the 
lower muscle weight observed for NR(SGA) at GD 135. 
Muscle hypertrophy depends upon intracellular protein turnover, which will 
favor protein deposition if protein synthesis rates are higher than protein degradation 
rates. Results from a sheep model of fetal glucose restriction during the last 40% of 
pregnancy have shown an upregulation of mRNA expression of the ubiquitin ligases 
FBXO32 and TRIM63 in fetal skeletal muscle (Brown et al., 2014). These markers 
participate in the ubiquitin-proteasomal pathway, which is the main pathway responsible 
for myofibrillar protein degradation (Sandri, 2013). Interestingly, the study of Brown et 




accounts for a percentage of protein degradation in muscle and no downregulation in 
pathways for protein synthesis.  
Glucocorticoids induce skeletal muscle catabolism and have been shown to 
upregulate FBXO32 and TRIM63 by binding to their receptor (NR3C1).  Binding to the 
NR3C1 receptor upregulates expression of the starvation-sensitive factor KLF15 and 
FOXO1. KLF15 further induces transcription of FOXO1 and directly upregulates 
FBXO32 and TRIM63 (Shimizu et al., 2011). Cortisol is an endogenous glucocorticoid 
that plays an essential role in prepartum fetal maturation (Vaughan et al., 2018). It has 
also been demonstrated that fetal cortisol increases in response to intrauterine stressors 
such as hypoxia, without increases in maternal cortisol (Challis et al., 1989). These 
findings indicate responsiveness of the fetal adrenal gland to intrauterine stress 
conditions. However, the results of the present study indicate no differences in fetal 
cortisol concentration levels at GD135 in response to the nutritional stress imposed by 
our NR treatment. 
 In the gastrocnemius muscle, an upregulation in NR3C1 mRNA was found in 
NR(SGA) compared to control. Having an upregulation in the receptor may increase 
glucocorticoid signaling regardless of the lack of differences in cortisol. We also 
observed an upregulation of KLF15 mRNA expression in both NR(SGA) and NR(Non-
SGA) groups compared to control. This suggests that upregulation in glucocorticoid 
signaling may have been achieved by upregulation of NR3C1. 
Similarly, we found upregulation of FOXO1 in NR(SGA) compared to control in 




were no differences in either total or phosphorylated protein levels of FOXO1, 
suggesting an absence of biological effect regardless of the upregulation at the gene 
expression level. This is consistent with our finding of no differences in mRNA 
expression of either FBXO32 or TRIM63 in gastrocnemius. For soleus muscle, there 
were no differences in NR3C1, while KLF15 was upregulated in NR(SGA) compared to 
control, but neither FOXO1, FBXO32, nor TRIM63 differed among groups. Hence, our 
results at the gene expression level do not provide supporting evidence for increased 
protein degradation mediated by muscle-specific ubiquitin proteins in either 
gastrocnemius or soleus muscles.  
In addition to its role in protein degradation, KLF15 regulates energetic 
metabolism in skeletal muscle, inducing a switch towards fatty acid utilization in 
response to starvation (Takeuchi et al., 2016). This is mediated by enhanced lipid flux to 
skeletal muscle and upregulation of fatty acid oxidation (Haldar et al., 2012). 
Lipoprotein lipase (LPL) is an enzyme that releases fatty acids from circulating 
triglycerides for their absorption in different tissues (Kim et al., 2001). Here we 
measured expression of LPL as an initial indicator for fatty acid uptake capacity in fetal 
skeletal muscle in response to starvation. Results show an upregulation of LPL in both 
NR(SGA) and NR(Non-SGA) compared to control within gastrocnemius muscle. This 
may indicate a higher capacity for fatty acid uptake and metabolic programming in favor 
of fatty acid oxidation in this tissue. Interestingly, no differences in LPL expression were 




Soleus and gastrocnemius muscles are expected to differ in metabolic 
characteristics because of their myofiber type composition. Soleus is formed primarily 
by type I myofibers while a mix between type I and type II myofibers is found in 
gastrocnemius. A mixed myofiber type composition provides higher metabolic plasticity 
between oxidative and glycolytic metabolism.  Importantly, a majority of muscles in the 
body are closer to this mixed phenotype rather than the more homogenous phenotype of 
the soleus (Ogata and Mori, 1964; Maltin 2008). Thus, the upregulation of LPL in 
NR(SGA) and NR(Non-SGA) in gastrocnemius muscle may have an impact on whole-
body metabolism. This is of particular relevance since it has been described that 
overexpression of LPL in skeletal muscle is associated with insulin resistance (Kim et 
al., 2001). 
It is of special interest that LPL and KLF15 were upregulated in both, NR(SGA) 
and NR(Non-SGA) groups within gastrocnemius muscle. Low fetal weight has typically 
been associated with negative metabolic programming and was the feature characteristic 
used to determine experimental groups in the initial studies in the field (Barker et al., 
1989). Our results add to a growing body of literature that having a normal fetal weight 
may not necessarily mean an absence of programming effect at the molecular level, 
which may lead to physiological alterations in postnatal life. Metabolic characterization 
at the skeletal muscle and whole-body level in NR(SGA) and NR(Non-SGA) was 
beyond the scope of the present study, but it warrants further research. Future findings 




depends primarily on fetal weight, but our current results suggest that this may not be 
completely accurate. 
Another downstream effect of KLF15 activation is upregulation of BCAT2 
(Shimizu et al., 2011), which mediates the first step of BCAA (leucine, valine, 
isoleucine) degradation in muscle. This has an impact on glucose homeostasis as BCAA 
are the primary donors of amino groups for the synthesis of alanine and glutamine in 
skeletal muscle, which are subsequently used as precursors in the liver (Garber et al., 
1976). We found no differences in BCAT2 expression within gastrocnemius muscle. 
However, there was an increase in total content of BCAA, and a higher concentration of 
leucine in NR(Non-SGA) fetuses compared with NR(SGA). This indicates an increased 
precursor availability for glutamine and alanine synthesis and release from skeletal 
muscle. Accordingly, there was a tendency towards increased concentrations of alanine 
and glutamine in NR(Non-SGA), and an increase in total contents of those amino acids 
in NR(Non-SGA) fetuses. This may support gluconeogenesis in these fetuses to 
counteract nutritional hardship. Activation of fetal gluconeogenesis has already been 
demonstrated in response to a chronic hypoglycemia model associated with placental 
insufficiency (Rozance et al., 2007).  
 In soleus muscle, there was an upregulation of BCAT2 in both NR(SGA) and 
NR(Non-SGA) fetuses. This result can be interpreted as an attempt to protect glucose 
homeostasis in response to maternal NR, independent of fetal growth capacity. However, 




majority of muscles in the body are metabolically more similar to gastrocnemius than 
soleus muscle (Ogata and Mori, 1964).  
A cross-talk between upregulation of BCAT2 and MTOR has been previously 
described (Shimizu et al., 2011). BCAA, particularly leucine, and arginine activate 
MTOR activity, which induces protein translation (Suryawan et al., 2008). Since BCAT2 
degrades BCAA, the increase in its expression in soleus muscle may lead to inhibition of 
MTOR signaling. We also found decreased concentrations of leucine and arginine in 
fetal plasma of NR(SGA) fetuses compared to NR(Non-SGA), while total content of 
those amino acids was lower in the NR(SGA) group compared to both NR(Non-SGA) 
and controls. This suggests that downregulation of MTOR pathway is likely to occur in 
NR(SGA) fetuses. However, we found no differences in either total or phosphorylated 
MTOR in soleus muscle. Accordingly, there were no differences in either total or 
phosphorylated EIF4EBP1or RPS6, which are downstream targets of MTOR and induce 
protein translation when active. No differences were found in BCAT2 mRNA expression, 
and total or phosphorylated MTOR, EIF4EBP1, and RPS6 in gastrocnemius. 
Additionally, for both soleus and gastrocnemius, there were no differences in total or 
active MAPK3/1, which is also involved in the stimulation of protein synthesis in 
skeletal muscle (Yuan et al., 2017).  
Another negative regulator of muscle mass through MTOR inhibition is MSTN, 
which was downregulated in NR(SGA) compared to control group in soleus. We 
interpret this result as a potential muscle-specific attempt to compensate for low muscle 




downregulation of a single negative regulator is less likely to induce a net effect, as 
demonstrated by the lack of differences in MTOR signaling found in this study. There 
were no differences in MSTN mRNA expression in gastrocnemius. 
A previous study found a reduction in longissimus dorsi muscle weight and 
associated decrease in MTOR and RPS6KB1 protein phosphorylation in a sheep model 
of 50% NR between GD 28 and 78 (Zhu et al., 2004). Consistent with findings of the 
present study, however, we previously found no difference in MTOR signaling in the 
longissimus dorsi muscle at GD 125 using the same NR model as the present study 
(Keith et al., unpublished results).  Differences in observed changes in MTOR may be 
explained by different timing of the insult or evaluation at an earlier GD. Nevertheless, 
the results of Zhu et al. (2004) showed no increase in ubiquitinated protein, which 
supports our results against increased protein degradation by upregulation of the 
ubiquitin-proteasomal pathway.  
Intracellular protein turnover depends on the cycle of protein synthesis and 
degradation. Protein turnover is affected by several factors and will favor protein 
deposition when protein synthesis is enhanced over protein degradation. Examples of 
factors that will affect protein turnover are the availability of amino acids and energy 
substrates within a cell, and the presence of anabolic signals (Wu, 2013a). Our results do 
not support differences in pathways for protein degradation or synthesis between our 
experimental groups, regardless of decreased cross-sectional area in NR(SGA) fetuses. 
Protein synthesis is an energetically expensive process (Rattray and Joyce, 1976) that 




50% maternal NR in the sheep reduced amino acid concentrations in maternal plasma 
and fetal plasma, allantoic and amniotic fluids (Kwon et al., 2004; Satterfield et al., 
2009; Satterfield et al., 2013). Here we found a decrease in total amino acid 
concentration in NR(SGA) compared to NR(Non-SGA) and a decrease in amino acids 
total content in NR(SGA) compared to both NR(Non-SGA) and controls. This indicates 
a scarcity of building blocks for protein synthesis in NR(SGA) fetuses, which may limit 
this process regardless of MTOR signaling activation. This is supported by the study of 
Manjarin et al. (2018) which found that lower rates of protein synthesis in skeletal 
muscle of porcine neonates under energy and protein restriction, without downregulation 
of MTOR signaling. Considering that intracellular protein turnover is continuously 
occurring within the cell, limited protein synthesis will result in intracellular protein loss, 
and overall would impair myofiber hypertrophy. 
 Lower protein synthesis rates would affect both skeletal muscle and fetal weight 
as amino acids play an essential role in conceptus and fetal growth and survival (Lin et 
al., 2014). Interestingly, administration of sildenafil citrate to 50% NR ewes was 
effective to increase amino acids in fetal serum, allantoic and amniotic fluids, and 
prevented the appearance of SGA fetuses (Satterfield et al., 2009). This is a promising 
finding to prevent SGA offspring in NR pregnancies. 
The increase in total content of amino acids in the NR(Non-SGA) group is of 
high relevance as it may indicate a unique materno-placental adaptation for enhanced 
amino acid transport in NR(Non-SGA) fetuses to counteract nutritional hardship. 




precursor for polyamines and nitric oxide, and these molecules are essential in fetal 
growth because of their angiogenic activity which supports nutrient delivery to the fetus 
through placental tissues (Wu et al., 2009). Thus, increased arginine availability would 
further support an adaptation towards enhanced fetal growth in NR(Non-SGA) fetuses. 
Arginine has also been positively associated with muscle growth by enhancing 
protein deposition (Tan et al., 2009) and it stimulates myoblast proliferation (Kalbe et 
al., 2013) and fusion (Long et al., 2006). Hence, it is possible that lower arginine in 
NR(SGA) group led to decreased myoblast proliferation, limiting muscle growth 
because of reduced myofiber formation. Also, decreased myoblast fusion capacity may 
lead to lower myonuclei content per myofiber, which would explain the decreased cross-
sectional area seen in NR(SGA) group because each myonucleus can support a fixed 
amount of cytoplasm within a myofiber. Further studies are warranted to explore this 
possibility and to study the effect of our model in myofiber formation in NR(Non-SGA) 





CHAPTER III                                                                                                            
EFFECT OF MATERNAL NUTRIENT RESTRICTION ON EXPRESSION OF 
GLUCOSE TRANSPORTERS (SLC2A1 AND SLC2A4) AND INSULIN 




Maternal nutrient restriction (NR) is a cause of small for gestational age (SGA) 
offspring which exhibit accelerated growth in early postnatal life (De Blasio et al., 
2007), and are at a higher risk of metabolic disease in adulthood (Barker and Clark, 
1997; Ozanne and Hales, 1999). Associated metabolic diseases include insulin resistance 
(Ozanne and Hales, 1999; Gardner et al., 2005; Todd et al., 2009), type II diabetes 
(Hales and Barker, 1992; Rich-Edwards et al., 1999), cardiovascular disease (Barker et 
al., 1989), and obesity (Fernandez-Twinn and Ozanne, 2006). The thrifty phenotype 
hypothesis suggests that the onset of metabolic syndrome in response to maternal NR is 
programmed via fetal adaptations to nutrient scarcity. Affected fetuses would have 
modified pathways for nutrient uptake and storage, such as insulin signaling, and 
glucose transport and utilization (Hales and Barker, 1992) which may be beneficial 
during prenatal and early postnatal life. Nevertheless, if nutrient availability increases 
during postnatal life, there is a mismatch between the anticipated phenotype and the 




uptake, increased adiposity and intracellular fat infiltration, and transition into insulin 
resistance in aged offspring. 
Fetal skeletal muscle is among the most susceptible tissues to maternal 
undernutrition because ‘vital organs’ are energetically prioritized in conditions of 
nutrient scarcity (Desai et al., 1996). Thus, skeletal muscle mass, metabolism, and 
myofiber type composition are likely to be altered by maternal NR. This has a 
detrimental effect on glucose metabolism since roughly 80% of insulin-mediated glucose 
uptake occurs in this tissue (Ferrannini et al., 1985). Impairment of skeletal muscle 
insulin sensitivity and glucose metabolism can lead to whole-body insulin resistance, 
which is one of the factors leading to type 2 diabetes and onset of metabolic syndrome 
(DeFronzo and Tripathy, 2009). 
The main glucose transporter in fetal tissues, including fetal skeletal muscle, is 
solute carrier family 2 member 1 (SLC2A1) (aka GLUT1) (Santalucia et al., 1992) 
which is insulin-independent. Nevertheless, by the end of gestation solute carrier family 
2 member 4 (SLC2A4) (aka GLUT4) starts to be upregulated in skeletal muscle and is 
the predominant glucose transporter in this tissue during postnatal life (Stuart et al., 
2000).  SLC2A4 is an insulin-dependent transporter which becomes active after 
translocation to the plasma membrane in response to activation of the PIK3CA/AKT 
pathway by insulin (Kohn et al., 1996). IGF1 can also trigger the activation of 
PIK3CA/AKT pathway (aka PI3K/AKT) by binding to its receptor or to INSRB (Mora 




Previous research has shown an upregulation in molecules involved in insulin 
signaling and glucose transport in skeletal muscle of fetuses born to NR dams at the fetal 
or early postnatal stage (Ozanne et al., 1996; Costello et al, 2008; Lie et al, 2014), while 
insulin resistance has been reported in aged offspring (Gardner et al., 2005). An increase 
in type II myofibers has also been found in response to maternal NR (Zhu et al., 2006).   
An increase in type II myofibers would impair glucose metabolism because these 
myofibers have lower insulin sensitivity and oxidation capacity than type I myofibers 
(He et al., 2001). These results are consistent with the establishment of a thrifty 
phenotype at the skeletal muscle level and its progression to metabolic syndrome. 
The vast majority of published studies have typically considered fetuses from NR 
dams as a single experimental group irrespective of their individual rates of fetal growth. 
In our studies, the NR sheep model yields a spectral phenotype of fetal growth rates, 
likely due to inherent abilities within the ewe to adapt to the nutritional hardship in an 
effort to support fetal growth.  Due to these observations, we sought to characterize 
mechanisms by which the placenta is capable of adapting to nutritional hardship and the 
resultant responses by the fetus (Keith et al., unpublished results). The aim of the present 
study was to evaluate the effect of differential responses to maternal NR on the 
expression of glucose transporters (SLC2A1 and SLC2A4), insulin signaling molecules 







2. Materials and Methods 
All experimental procedures in this study were approved by the Institutional 
Agricultural Animal Care and Use Committee of Texas A&M University. 
2.1 Animal Handling and Tissue Collection  
Mature Hampshire ewes of similar frame size, parity, and body condition were 
fed to meet 100% of their nutritional requirements according to recommendations of the 
National Research Council (NRC) and used as embryo transfer recipients. A protocol for 
estrus synchronization and superovulation was administered to recipient and donor ewes. 
Hampshire donor ewes were artificially inseminated, and on gestational day (GD) 6, a 
single embryo was transferred from a donor ewe into the recipient uterus. Ultrasound 
was used as pregnancy diagnostic on GD 28. On GD 28, ewes were housed in individual 
pens on concrete and maintained in these conditions until GD 135. Ewes were fed once 
per day. Rations were adjusted once per week based on weekly measurements of body 
weight. On GD 35, ewes were randomly divided into a control-fed group which received 
100% NRC requirements, and a nutrient-restricted (NR) group, which received 50% of 
total NRC requirements. Composition of the diet has been published previously (Lassala 
et al., 2010). Necropsies were conducted on GD 135. At this time, blood samples from 
fetal umbilical vein and fetal heart were collected to obtain fetal plasma. Soleus and 
gastrocnemius muscles were dissected and weighed, and samples preserved for further 
investigation. 
Fetuses from ewes fed 100% NRC formed the Control group (n=12). Fetuses 




(NR(Non-SGA) group; n=11) and lowest (NR(SGA) group; n=11) quartiles were 
selected for further investigation (Keith et al., unpublished results). 
 2.2 Glucose, Insulin, and IGF1 Concentration in Fetal Plasma  
Glucose, insulin, and IGF1 concentrations in plasma were measured using, a 
glucose colorimetric kit (catalog number STA-680, Cell Biolabs, Inc., San Diego, CA), 
insulin ELISA (catalog number 80-INSOV-E01, ALPCO Diagnostics, Salem, NH), and 
IGF1 ELISA (catalog number SI0016, Neo Biolabs, Cambridge, MA) respectively. All 
kits were used according to manufacturer recommendations (Satterfield et al., 2013).  To 
calculate total hormone and nutrient content in the fetal circulation, concentrations were 
multiplied by blood volume, which was estimated at 110ml/kg fetal weight (Brace, 
1983; Brace, 1986). 
2.3 Protein Extraction and Western Blots 
Total protein from soleus and gastrocnemius muscles were extracted by tissue 
homogenization in lysis buffer using snap-frozen samples. Protein concentration was 
measured using Bradford protein assay (Bio-Rad Laboratories, Inc., Hercules, CA) using 
BSA as standard. Total INSRB (1:250, catalog number SC-81465, Santa Cruz 
Biotechnology, Dallas, TX), IGF1R (1:2000, catalog number ab182408, Abcam, 
Cambridge, MA), AKT and phosphorylated AKT (1:1000, catalog numbers 9271 and 
9272, Cell Signaling Technology, Danvers, MA), SLC2A4 (1 µg/mL, catalog number 
ab33780, Abcam, Cambridge, MA), and SLC2A1 (1:50000, catalog number Ab115730, 
Abcam, Cambridge, MA) were quantified by western blots as previously described 




antibody (1:20000 of 1mg/ml stock) (KPL, Bethesda, MD) followed by incubation on 
SuperSignalTM West Dura (Thermo Scientific, Waltham, MA) were used to detect 
immunoreactive proteins by chemiluminescence. Proteins were quantified using 
Quantity One® 4.6.1 Software (Biorad Laboratories, Inc., Hercules, CA) with tubulin 
(1:10000, catalog number Ab7291, Abcam, Cambridge, MA) and GAPDH (1:10000, 
catalog number 2118, Cell Signaling Technology, Danvers, MA) as loading controls for 
soleus and gastrocnemius respectively. 
 2.4 Immunofluorescence 
 SLC2A4 translocation and myofiber type composition were evaluated by 
immunofluorescence. A modification of the protocol described by Wang et al. (2014) 
was used. Briefly, one section of 8 µm was obtained per sample using a cryostat at -
16oC, fixed in cold methanol for 10 minutes, and blocked using 10% normal goat serum 
for 1 hour at room temperature. After that, a cocktail of three antibodies against laminin 
(1:300, catalog number Ab44941, Abcam, Cambridge, MA), SLC2A4 (1:500, catalog 
number Ab33780, Abcam, Cambridge, MA), and Type I myosin heavy chain (1:75 for 
gastrocnemius, 1:50 for soleus, catalog number BA-D5, Developmental Studies 
Hybridoma, University of Iowa) was added for overnight incubation at 4°C. Mouse, rat, 
or Rabbit IgG were substituted for the primary antibody as a negative control. A cocktail 
of secondary antibodies (1:500, Alexa Fluor 488®, 594®, and 350®, Thermo Fisher 
Scientific, Waltham, MA) was then added for one hour of incubation at room 
temperature. Slides were overlaid using Prolong Antifade (Life Technologies, Carlsbad, 




 Eight non-overlapping areas were imaged and evaluated per each section, using a 
Nikon Eclipse Ni-E fluorescence microscope and NIS-Elements AR 4.30.02 64-bit 
Software (Nikon Instruments Inc., Melville, NY). Colocalization between SLC2A4 and 
laminin was used as an indicator of SLC2A4 translocation. For myofiber type 
composition, any stained myofiber (blue) was identified as type I while non-stained 
myofiber was counted as type II. Results are expressed as Type I/Type II myofiber ratio.  
2.5 Statistical Analysis 
Data were analyzed using JMP® Pro 14 software (SAS Institute Inc., Cary, NC). 
One-way ANOVA (α= 0.05) analysis was used to compare the means of control, 
NR(SGA), and NR(Non-SGA) groups. Differences between specific means were 
evaluated using Tukey’s test.  
3. Results 
3.1 Glucose, Insulin, and IGF1 Concentration and Total Content in Fetal 
Plasma 
We have previously reported that fetuses from NR ewes having SGA offspring 
were smaller (P<0.05) than fetuses from NR ewes having Non-SGA fetuses and control-
fed females, which had similar weights to one another. Here we found no differences in 
either glucose concentration (mg/dL) (P=0.3500) or total glucose content (mg) 
(P=0.2376) in fetal plasma between groups (Figure 3.1A and 3.1D). Insulin 
concentration (ng/ml) in fetal plasma was lower (P=0.0055) in the NR(SGA) group than 
in the control group, while Non-SGA fetuses were not different from either NR(SGA) or 




compared to both control (P=0.0003) and NR(Non-SGA) (P=0.0422) groups (Figure 
3.1E). IGF1 concentration in fetal plasma was not different between groups (P=0.2899) 
(Figure 3.1C). However, estimated total IGF1 levels were decreased in NR(SGA) group 
in comparison to control (P=0.0132), while NR(Non-SGA) was not different from either 
NR(SGA) or control (P>0.05) (Figure 3.1F). 
 3.2  Protein Expression 
We have previously reported a reduction (P<0.05) in fetal gastrocnemius and 
soleus weight in NR(SGA) group compared to control and NR(Non-SGA) fetuses at GD 
135. Here we found that within the gastrocnemius muscle, INSRB protein levels were 
greater in fetuses from the NR(SGA) in comparison to fetuses in the NR(Non-SGA) 
group (P=0.0285). INSRB content in fetuses from control fed ewes was not different 
between groups (Figure 3.2A). IGF1R protein levels were higher fetuses from the 
NR(SGA) group compared to fetuses from control-fed ewes (P=0.0059), while its 
content in fetuses from the NR(Non-SGA) group did not differ from either NR(SGA) or 
control (Figure 3.2B). Neither total nor phosphorylated AKT levels differed between 
groups (P=0.6500) (Figure 3.2C). SLC2A4 and SLC2A1 protein were higher (P=0.0110 
and P=0.0383, respectively) in fetuses from the NR(SGA) group than fetuses from the 
NR(Non-SGA) group, while fetuses from the control group did not differ between either 
NR(SGA) or NR(Non-SGA) groups (Figure 3.3A and 3.3B).  
In soleus muscle, there were no differences in INSRB (P=0.3690), IGF1R 
(P=0.5857), total AKT, phosphorylated AKT and their ratio (P=0.9042) (Figure 3.2D, 







Figure 3.1 Plasma Concentration and Total Glucose, Insulin, and IGF1 at GD 135. 
(A), (B), and (C) show variations per group in fetal plasma concentrations of glucose, 
insulin, and IGF1, respectively. (D), (E), and (F) show estimated total content of 
glucose, insulin, and IGF1, respectively. Data is shown as X̅±SEM. Means without a 










Figure 3.2 Protein Expression of PIK3CA/AKT Pathway Signaling Molecules in 
Fetal Muscles at GD 135. Insulin receptor β (INSRB), IGF1 receptor (IGF1R), and the 
ratio between total and phosphorylated AKT protein expression in gastrocnemius muscle 
are shown in (A), (B), and (C) respectively. INSRB, IGF1R, and the ratio between total 
and phosphorylated AKT levels in soleus muscle are shown in (C), (D), and (E) 
respectively. Data is shown as X̅±SEM. Means without a common superscript between 
Control, NR(Non-SGA), and NR(SGA) differ (P<0.05). Total and phosphorylated AKT 























Figure 3.3 Protein Expression of Glucose Transporters in Fetal Muscles at GD 135. 
SLC2A4 and SLC2A1 protein levels in gastrocnemius muscle are shown in (A) and (B) 
respectively. SLC2A4 and SLC2A1 protein levels in soleus muscle are shown in (C) and 
(D) respectively. Data is shown as X̅±SEM. Means without a common superscript 







3.3  SLC2A4 Translocation 
For both, gastrocnemius and soleus (Figure 3.4A and 3.4B) muscles, SLC2A4 
localization by immunofluorescence did not show observable differences among 
NR(SGA), NR(Non-SGA) and control groups. In addition, there was scarce overlapping 
between SLC2A4 and laminin staining, which indicates that there was no major 
translocation of SLC2A4 occurring at GD 135 in the fetus. 
3.4  Myofiber Type Composition 
The relative number of type I myofibers (Type I/Type II ratio) in gastrocnemius 
muscle was lower in fetuses from the NR(SGA) group compared to fetuses from both, 
NR (Non-SGA) (P=0.0046) and control (P=0.0196) groups. In the soleus muscle, fetuses 
from the NR(SGA) group had a lower Type I/Type II ratio than control (P=0.0145), 
while type I relative content was intermediate in NR(Non-SGA) fetuses and not different 




Table 3.1 Relative Myofiber Type Composition per Group in Gastrocnemius and 
Soleus Muscles at GD 1351 
1Means represent the ratio between type I and type II myofibers in Control, NR(Non-
SGA), and NR(SGA). Data is shown as X̅±SEM. Different superscripts indicate P<0.05. 
 
Tissue Control 
(Type I/Type II) 
NR(Non-SGA) 
(Type I/ Type II) 
NR(SGA) 
(Type I/ Type II) 
Gastrocnemius 0.25±0.002a 0.26±0.002a 0.16±0.002b 




Figure 3.4 SLC2A4 Localization and Myofiber Type Identification in Fetal Muscles 
at GD 135. Immunoreactive proteins for SLC2A4 (Red), Laminin (Green), and Type I 
Myosin Heavy Chain (Blue) are shown for Gastrocnemius (A) and Soleus (B). White 
arrows indicate examples of Type I myofibers. Laminin was used as a plasma membrane 
marker to colocalize SLC2A4 and evaluate its translocation. For the IgG control (not 
shown), normal rabbit, rat, and mouse IgGs were substituted for the primary antibody, 








 The objective of the present study was to evaluate the effect of differential 
responses to maternal NR on glucose transporters, insulin signaling molecules, and 
myofiber type composition in fetal skeletal muscle, which could set metabolic alterations 
that ultimately lead to increased risk for disease during postnatal life. Results highlight 
molecular differences between SGA and Non-SGA fetuses receiving the same prenatal 
NR treatment, likely suggesting a differential ability of the dam to support fetal growth 
during hardship which may convey resistance to metabolic disease in the adult offspring. 
This study also confirms previous findings regarding the relative resistance of the fetal 
soleus muscle to maternal NR (Ward and Stickland, 1991 and Costello et al., 2008) as 
the only affected characteristic in this muscle was myofiber type composition.  
 Insulin is an anabolic hormone involved in glucose and amino acid uptake in the 
body (Dimitriadis et al., 2011). During the fetal stage, insulin in the fetal circulation is 
positively correlated with fetal growth (Fowden et al., 1989). It has been previously 
found that maternal nutrient restriction from GD50 to term induces a reduction in fetal 
insulin (Vonnahme et al., 2010). Similarly, the present study showed a decrease in 
plasma insulin concentration in NR(SGA) fetuses compared to control, and a marked 
reduction in total insulin in NR(SGA) fetuses compared to both, NR(NonSGA) and 
control. Lower insulin levels in NR(SGA) group suggest a reduction in anabolic signals 
in these fetuses, which is manifest in the reduction in fetal growth seen in this group, and 
likely indicate increased risk for alterations in glucose metabolism and development of 




 Circulating glucose levels are the main trigger for insulin secretion from pancreas 
(Hellman et al., 1994). This study found no effects of maternal NR on fetal glucose 
plasma concentration or estimated total; hence, hypoglycemia was not the cause for the 
reduced insulin content in NR(SGA) group. Other nutrients, such as amino acids have 
also been found to induce insulin secretion  (Floyd et al., 1966; Newsholme et al., 2006). 
Particularly leucine, a BCAA, and arginine can induce pancreatic insulin release 
(Schmidt et al., 1992; Kalogeropoulou et al., 2008). Using a model of 50% maternal NR, 
it has been previously described that concentrations of arginine, branched-chain amino 
acids (BCAA), and total amino acids are reduced in fetal plasma, amniotic and allantoic 
fluids at GD135 (Kwon et al., 2004). 
 Similarly, we have previously described lower concentration and total content of 
arginine and leucine in NR(SGA) fetuses. Thus, a decrease of circulating amino acids in 
response to maternal NR cannot be ruled out as a cause for impaired insulin release in 
this group. Altered capacity of the pancreatic beta-cell to release insulin has previously 
been described in intrauterine growth-restricted fetuses induced by placental 
insufficiency (Limesand et al., 2006). Likewise, 50% maternal NR has been associated 
with decreased pancreatic beta-cell mass in a rat model (Garofano et al., 1997), and a 
similar response could have been induced by our treatment.  Interestingly, it has been 
demonstrated that administration of arginine to 50% NR ewes is effective to enhance 
fetal pancreas growth (Satterfield et al., 2013). In addition, sildenafil citrate treatment 
has been shown to increase the availability of amino acids and fetal growth in fetuses 




counteract the negative effect of maternal NR on fetal and pancreas growth, likely 
decreasing the risk of metabolic disease in adulthood.  
 Insulin exerts its anabolic effect in part by upregulating the PIK3CA/AKT 
pathway after binding to its receptor. Activation of AKT induces translocation of 
SLC2A4, which stimulates insulin-mediated glucose uptake. Upregulation of INSRB 
protein content (Gardner et al., 2005) and mRNA expression (Costello et al., 2008) have 
been previously described in sheep fetal skeletal muscle in response to maternal NR. 
Likewise, we found that within gastrocnemius, INSRB protein content was upregulated 
in the NR(SGA) group compared to NR(Non-SGA). This indicates that results from our 
NR(SGA) group are concordant with previous findings for NR fetuses. More 
importantly, this suggests that our NR(Non-SGA) group may represent a unique 
phenotype that is not equally affected the maternal NR in terms of fetal weight, and 
likely will not experience the same metabolic dysregulations than NR(SGA) in 
adulthood. However, is still unknown until which extent the NR(Non-SGA) group is 
protected from maternal NR programming, or how the potential adaptations that support 
fetal growth in early life may lead to other negative health outcomes during postnatal 
life.  
 We interpret our finding of increased INSRB in NR(SGA) group as an attempt to 
compensate for lower insulin availability. This possibility is supported by the lack of 
differences seen in total, or phosphorylated (active) AKT, or their ratio, in this study. 
AKT activation can also stimulate the MTOR pathway for protein synthesis (Boucher et 




MTOR pathway, and our current results for AKT further support that finding. AKT can 
also be phosphorylated in response to other ligands that activate the PIK3CA/AKT 
pathway, such as IGF1 (Manning and Toker, 2017). Thus, a potential amplification of 
insulin signaling by upregulation of INSRB is not the only possible cause for the 
absence of differences in active AKT. 
 Additionally, the upregulation of INSRB seen in this study could have a role in 
the short period of enhanced insulin sensitivity that has been suggested to happen in 
early postnatal life of SGA offspring, before progression towards insulin resistance in 
adulthood (Geremia and Cianfarani, 2004; Ibáñez et al., 2006; Morrison et al., 2010). 
The present study also observed a reduction of total IGF1 in NR(SGA) group compared 
to control, while NR(Non-SGA) had intermediate levels and did not differ from the other 
two groups. IGF1 has an anabolic role in fetal growth as its concentration shows a 
positive correlation to fetal size (Verhaeghe et al., 1993) and its deficiency can induce 
intrauterine growth retardation (Baker et al., 1993). Moreover, an intraamniotic 
administration of IGF1 has been shown to increase fetal growth in a model of prenatal 
growth restriction induced by placental embolization (Wali et al., 2012). Thus, as 
previously discussed for insulin, a decrease of total IGF1 in the NR(SGA) group is likely 
one of the alterations correlated to the intrauterine growth retardation in these fetuses. 
IGF1 exerts its action by binding to IGF1R preferentially, and to insulin receptor but 
with lower affinity (Belfiore et al., 2009). This growth factor can also activate the 
PIK3CA/AKT pathway in several tissues, including skeletal muscle (Schiaffino and 




the NR(SGA) group compared to controls. This follows a similar pattern than previously 
described for insulin and INSRB and further supports the establishment of a 
compensatory response in fetuses from the NR(SGA) group to account for the 
circulating levels of anabolic hormones. 
 SLC2A4 is among the most abundant glucose transporters expressed in skeletal 
muscle (Stuart et al., 2000), and its action is insulin dependent (James et al., 1988). 
Activation of the PIK3CA/AKT pathway induces SLC2A4 translocation to the 
sarcolemma where it exerts its glucose transport function. Previous studies have 
demonstrated an upregulation of SLC2A4 mRNA in skeletal muscle of sheep fetuses in 
response to a maternal NR treatment applied during late gestation (Costello et al., 2008) 
or the preimplantation period (Lie et al., 2014). Similarly, results of the present study 
found an upregulation of SLC2A4 protein content in NR(SGA) compared to NR(Non-
SGA) fetuses within gastrocnemius muscle, suggesting a compensatory response to the 
reduction in insulin. However, the lack of evident differences in SLC2A4 translocation 
among groups suggests that there is probably no net effect on glucose transport at 
GD135 in this specific tissue. 
  During postnatal life, an increase in nutrient availability may increase insulin 
secretion to induce SLC2A4 translocation. Exercise also stimulates translocation of this 
glucose transporter, and its effect would become relevant postnatally by incorporation of 
locomotion (Garg et al., 2009). Thus, we anticipate that under postnatal conditions the 
upregulation in SLC2A4 will lead to enhanced glucose uptake in skeletal muscle of 




that is typically seen postnatally in SGA fetuses (De Blasio et al., 2007). Likewise, we 
found the same expression pattern for SLC2A1, which is an insulin-independent glucose 
transporter that is expressed at lower levels than SLC2A4 in adult skeletal muscle, but it 
is highly expressed in fetal tissues (Santalucia et al., 1992). This would further boost 
glucose uptake capacity within gastrocnemius muscle in NR(SGA) fetuses.  
 In soleus muscle, there was no upregulation in either INSRB, IGF1R, AKT, 
SLC2A4, or SLC2A1. These results support the relative resistance of this muscle to 
prenatal undernutrition, which has previously been described in the literature (Ward and 
Stickland, 1991; Costello et al., 2008). The majority of myofibers in the soleus are 
formed during primary myogenesis which occurs in early pregnancy, likely been 
relatively protected from the effects of maternal NR. However, most of the developing 
muscles, including the gastrocnemius, are composed of a higher proportion of secondary 
myofibers, which begin to form by GD 62 in the sheep and are more prone to be affected 
by maternal NR (Ward and Stickland, 1991). Also, in the adult organism, most of the 
muscles, including gastrocnemius, are formed by a mix of type I and type II myofibers, 
instead of almost exclusively having one of them, while soleus is primarily composed of 
type I myofibers once it acquires expression of adult myosin heavy chain (Ogata and 
Mori, 1964; Maltin, 2008). This suggests that our findings within gastrocnemius muscle 
are more likely to represent the response of most muscles in the body, which may lead to 
a whole-body metabolic programming effect.  
 Myofiber type composition influences muscle metabolism because it has an 




et al., 2001). Specifically, type I myofibers are oxidative and have higher insulin 
sensitivity than type II myofibers. A decreased proportion of type I myofibers has 
previously been found at GD 127 in fetal triceps brachii muscle in response to 50% NR 
in sheep (Costello et al., 2008). Likewise, our results indicate a lower proportion of type 
I myofibers in NR(SGA) group compared to both, control and NR(Non-SGA) in 
gastrocnemius muscle. Similarly, for soleus muscle, type I myofiber proportion was 
lower in NR(SGA) compared to control, while NR(Non-SGA) showed an intermediate 
proportion and did not differ from the other two groups. 
 Poly-neuronal innervation of myofibers has been described at the fetal stage, 
which may lead to co-expression of characteristics of different myofiber types in the 
same cell (Redfern, 1970). Poly-neuronal innervation disappears by the second week of 
postnatal life in rats (Brown et al., 1976), and likely during late pregnancy in precocial 
species such as the sheep. Hence, prenatal observations regarding myofiber type 
composition may not represent the adult stage, but if our results for myofiber type 
composition are maintained in postnatal life, it could impair insulin sensitivity at the 
skeletal muscle level, primarily in the NR(SGA) group, which could lead to whole-body 
metabolic alterations in glucose homeostasis. This is supported by previous research 
suggesting that an increased proportion of type II myofibers is associated with insulin 
resistance in skeletal muscle (Nyholm et al., 1997), and that altered insulin sensitivity in 
peripheral tissues is among the first noticeable alterations in the progression to insulin 




 Interestingly, a treatment of 50% NR from GD 28 and GD 78 in sheep has been 
associated to increased content of type IIb myofibers in longissimus dorsi of 8-month-
old offspring (Zhu et al., 2006). This suggests a long-lasting effect of prenatal NR on 
myofiber composition. However, contradictory results have been found in longissimus 
dorsi of 14-day-old lambs in which an increase in type I myofibers was found after 50% 
NR from GD 30 to 70 (Fahey et al., 2005). This divergence may be due to the 
differences in the treatment, or muscle used in the study. Also, postnatal conditions may 
influence results as myofiber type composition conserves a certain level of plasticity 
during postnatal life in response to some stimuli such as exercise. Thus, more research is 
still needed to confirm the long-lasting effect of myofiber type programming during fetal 
development (Brown, 2014). 
 Previous research suggests that prenatal programming for magnification of 
insulin-mediated glucose uptake sets up the conditions for insulin resistance in adult 
offspring (Costello et al., 2008). Intramuscular triglyceride (IMTG) accumulation is a 
cause for disruption in insulin signaling, and insulin resistance in skeletal muscle 
(Corcoran et al., 2007). We have previously found increased mRNA expression of 
lipoprotein lipase (LPL) in gastrocnemius muscle in both, NR(SGA) and NR(Non-SGA) 
groups compared to control. LPL is an enzyme that releases fatty acids from circulating 
triglycerides and its overexpression in skeletal muscle has been related to insulin 
resistance (Kim et al., 2001). Increased fatty acid uptake, together with lower oxidative 




to IMTG accumulation, and a possible cause for the onset of insulin resistance during 
























CHAPTER IV  
SUMMARY AND CONCLUSIONS 
 
1. Summary 
The initial studies on fetal programming identified epidemiological correlations 
between maternal undernutrition, low birth weight of the offspring, and increased risk 
for metabolic syndrome during adulthood (Barker 1989; Hales and Barker, 1992). These 
observations have been confirmed using animal models of maternal nutrient restriction 
to induce small for gestational age offspring (SGA). Several fetal organs are affected in 
response to maternal NR (Osgerby et al., 2002; Vonnahme et al., 2003; Lloyd et al., 
2012; Satterfield et al., 2013). Among them, skeletal muscle is of particular relevance 
because of its implications in glucose and oxidative metabolism, and because in an 
agricultural context, it has an impact on animal protein production for human 
consumption.  
Several authors have studied the effect of maternal NR on skeletal muscle (Zhu 
et al., 2004; Quigley et al., 2005; Fahey et al., 2005; Ford et al., 2007; Costello et al., 
2008; Lie et al., 2014). The vast majority of published studies have considered fetuses 
from NR dams as a single experimental group. However, our observations consistently 
indicate that the NR sheep model yields a spectral phenotype of fetal growth rates, likely 
due to inherent abilities within the ewe to adapt to the nutritional hardship and support 
fetal growth.  Due to these observations, we sought to characterize mechanisms by 




responses by the fetus. Hence, studies were conducted to characterize the response of 
fetal skeletal muscle to maternal NR using NR(SGA) and NR(Non-SGA) fetuses as 
experimental groups.   
We have confirmed our previous findings of unequal alterations of fetal weight 
in response to maternal NR and observed the same pattern for individual muscle weights 
in both, gastrocnemius and soleus muscles at GD 135. In CHAPTER II, we aimed to 
study the differences in skeletal muscle growth in terms of hypertrophy, and found that a 
decrease in myofiber cross-sectional area (CSA) in the NR(SGA) group was not 
associated with markers for upregulation in pathways for proteasomal protein 
degradation (glucocorticoid-KLF15-ubiquitin ligases pathway) or downregulation in 
pathways for protein synthesis (MTOR pathway). This last finding was supported by the 
lack of differences found in total or active AKT, which is a positive regulator of MTOR 
signaling (CHAPTER III).  
However, activation of MTOR signaling molecules is not necessarily associated 
with a sustained rate of protein synthesis under energy and protein restriction conditions 
(Manjarin et al., 2018). Interestingly, we found increased total content and concentration 
of total amino acids in NR(Non-SGA) group compared to NR(SGA) (CHAPTER II). 
Based on our observations, we suggest that an overall lack of amino acid availability in 
NR(SGA) fetuses would impair protein synthesis rates due to a reduction in available 
building blocks, without necessarily leading to a downregulation in markers of MTOR 
activation. This would explain, at least in part, the lower CSA found for NR(SGA) 




detrimental effect on fetal growth. The fact that NR(Non-SGA) fetuses had higher 
availability of amino acids compared to NR(SGA) is of seminal relevance as it may 
indicate a unique maternal-placental adaptation to enhance amino acid transport in an 
attempt to counteract nutritional hardship.  
Muscle weight at GD 135 may have also been affected by a lower number of 
myofibers. Studying myofiber formation was beyond the scope of the present studies 
because it occurs at an earlier gestational age, but our NR treatment from GD 35 to GD 
135 had the potential to impair myofiber formation. Of particular interest is the fact that 
concentration and total content of the amino acid arginine were reduced in NR(SGA) 
fetuses (CHAPTER II). Arginine is essential to promote placental, fetal, and skeletal 
muscle growth. It also has a positive effect on myoblast proliferation and fusion, which 
are relevant processes in myofiber formation. Thus, reduced arginine in the NR(SGA) 
fetuses may be correlated with a potential decrease in total myofiber dotation, which will 
further limit muscle growth in gastrocnemius and soleus muscles. 
Stimulation of fetal and skeletal muscle growth depends upon anabolic signals. 
Some amino acids, such as arginine and leucine have a stimulatory effect on the release 
of insulin, which is an anabolic hormone (Schmidt et al., 1992; Kalogeropoulou et al., 
2008). Here we found that both, concentration and total content of arginine and leucine 
were increased in NR(Non-SGA) compared to NR(SGA) fetuses (CHAPTER II). 
Accordingly, when we aimed to characterize the effect of our treatment on pathways for 
glucose uptake (CHAPTER III), we found lower total insulin in NR(SGA) fetuses 




acid signaling for insulin release may be impaired in NR(SGA) fetuses, leading to 
downregulation of anabolic signals which would affect both, fetal skeletal muscle and 
whole-body growth. Assessment of pancreas developmental programming is beyond the 
scope of the present studies, but alterations in this organ are also a likely cause for lower 
insulin levels in NR(SGA) fetuses. 
We also found lower total content of IGF1 in NR(SGA) fetuses compared to 
control, and interestingly there was an upregulation of both, INSRB and IGF1R in this 
group within gastrocnemius muscle (Chapter III). We interpret this result as an attempt 
to mount a compensatory response to counteract the lower content of anabolic hormones. 
This may be beneficial to sustain fetal life under nutrient scarcity conditions. SLC2A4 
and SLC2A1 were also upregulated within NR(SGA) compared to NR(Non-SGA) 
fetuses within gastrocnemius muscle. We anticipate that during early postnatal life, the 
upregulation of insulin and IGF1 receptors, SLC2A4, and SLC2A1 would provide the 
molecular basis for initial accelerated postnatal growth and establishment of a thrifty 
phenotype.  
Previous authors have indicated that upregulation of insulin signaling at the fetal 
stage would increase the risk of insulin resistance in postnatal life (Costello et al., 2008). 
Accumulation of intramuscular triglycerides is a cause for impairment in insulin 
signaling (Corcoran et al., 2007) and here we found an upregulation of LPL in both 
NR(SGA) and NR(Non-SGA) fetuses within gastrocnemius muscle. Similar results were 
found for KLF15 (CHAPTER II). In addition to the role of KLF15 in glucocorticoid-




starvation. One of the described effects is an increase in lipid utilization in skeletal 
muscle in an attempt to switch metabolism towards fatty acid oxidation and spare 
glucose. Thus, our results for KLF15 and LPL may indicate an enhanced lipid uptake in 
fetal skeletal muscle in response to starvation. However, oxidative capacity may be 
specifically impaired in NR(SGA) fetuses because of a lower proportion of type I 
myofibers. If these conditions are maintained during postnatal life, increased uptake of 
fatty acids together with decreased oxidative capacity may lead to lipid accumulation, 
and be a potential cause for insulin resistance during adulthood in NR(SGA) offspring.  
The fact that  LPL and KLF15 were upregulated in both, NR(SGA) and NR(Non-
SGA) is of particular relevance as it suggests that NR(Non-SGA) is not completely 
protected from the programming effect induced by maternal NR. This is supported by 
results for BCAT2 in soleus muscle, which is also upregulated in both NR groups 
compared to controls. However, the differences seen in INSRB, SLC2A1, SLC2A4, and 
myofiber type composition indicate a divergent response between NR(SGA) and 
NR(Non-SGA) within gastrocnemius muscle. This supports the fact that regardless of 
presenting a normal fetal weight, our NR(Non-SGA) group represents a unique 
phenotype, and is still unknown what metabolic alterations will be observed during 
adulthood as a consequence of this exclusive programming path.  
Here we have also confirmed the relative resistance of soleus muscle to maternal 
NR. Soleus and gastrocnemius muscles are expected to have different metabolic 
characteristics, and the majority of muscles in the body are likely to have a phenotype 




muscle as more representative of whole-body skeletal muscle mass. Our results highlight 
the relevance of considering muscle-specific responses when trying to extrapolate results 
from a single muscle to the whole body.  
2. Conclusions 
In conclusion, we observed that our maternal NR model leads to differential 
effects on NR(SGA) and NR(Non-SGA) fetuses in terms of muscle growth and 
metabolism. While the observed results for NR(SGA) fetuses agree with previous 
observations in the literature, our results for NR(Non-SGA) indicate a unique metabolic 
programming effect. Our results are an initial indicator that having normal fetal weight 
after prenatal NR does not necessarily indicate an absence of molecular programming, 
which may impair metabolism during adulthood to an unknown extent. Future studies 
using isotopic tracers would provide essential information to evaluate dynamic 
processes, such as protein synthesis rate, in order to further understand the implications 
of our current results at a whole-body level. Additionally, characterization of specific 
markers in organs other than skeletal muscle would facilitate the understanding of our 
current findings in an interorgan cross-talk context.  Further, understanding the maternal 
or placental adaptations that lead to the establishment of NR(Non-SGA) phenotype is of 
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